Method of inserting lubricant free stopper into lubricant free barrel or lubricant free cartridge tube, and system for assembling same
The lubricant-free stopper insertion method addresses contamination and failure risks in prefilled syringes by using a lubricant-free system with controlled surface properties and polymer layers, ensuring safe and reliable drug delivery.
Patent Information
- Application Number
- JP2024131052
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-06-18
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-26
AI Technical Summary
Conventional syringes used in prefilled drug delivery face challenges due to the use of lubricants like silicone, which can contaminate drugs, cause protein aggregation, and lead to syringe failure from manufacturing irregularities, posing risks to patient safety and device integrity.
A method for inserting a lubricant-free stopper into a lubricant-free barrel using an insertion tube and pin, ensuring the syringe components are free of lubricants, with specific surface roughness and kurtosis values to minimize damage and contamination, and incorporating a polymer layer for sealing and stability.
This approach reduces the risk of drug contamination, minimizes syringe failure, and ensures precise delivery of therapeutic compounds without lubricant-related issues, enhancing safety and reliability in prefilled syringes.
Smart Images

Figure 2024164055000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates generally to syringes and syringe assemblies, and more particularly to a method for inserting a lubricant-free stopper into a lubricant-free barrel (e.g., syringe) or a lubricant-free cartridge tube (e.g., cartridge). A system for assembling lubricant-free syringes and lubricant-free cartridges is also provided. [Background technology]
[0002] Pre-filled syringes function to both store and deliver drugs and / or biologics (e.g., pharmaceutical and / or biopharmaceutical therapies). Pre-filled syringes may also generally provide cost savings to the pharmaceutical industry and improve the safety, convenience, and efficacy of drug delivery. Biopharmaceuticals are a significant class of pharmaceuticals that may increase the use of pre-filled syringes and related devices, such as auto-injectors or injector pens (e.g., EpiPen®). Non-limiting examples of biopharmaceuticals include insulin, vaccines, antibodies, blood products, hormones, and / or cytokines. As more pharmaceuticals, particularly biopharmaceuticals, are utilized for delivery in pre-filled syringes and other pre-filled syringes, difficulties with the use of traditional syringe technology in pre-filled syringes have become apparent.
[0003] There are several aspects of conventional syringe constructions that present challenges to their use as pre-filled syringes. One is the use of silicone (e.g., silicone oil) and / or other lubricants. Traditionally, silicone provides a liquid seal between the stop and the syringe barrel. Although silicone has traditionally been used to ensure that the force required to actuate a pre-filled syringe or similar pre-filled injectable device is minimized, the use of silicone as a lubricant poses a risk of contamination. For example, silicone may degrade or contaminate drugs or biological materials within the injectable device. Additionally, silicone may be injected into a patient along with the drug. Silicone may be of particular concern with biopharmaceuticals, as it may cause aggregation of certain proteins, thereby rendering the biopharmaceutical unusable for injection.
[0004] A second aspect is the occurrence of small bumps or irregularities on the inner surface of the insertion tube, which may be present as a by-product of the insertion tube manufacturing process. Typically, these irregularities do not affect the stop, as the silicone in the insertion tube allows the stop to pass over the irregularities without issue. However, if silicone or other suitable lubricant is not applied or is inadvertently omitted, damage or destruction of the stop can cause failure of the syringe or similar injectable device.
[0005] Therefore, what is needed is a method for inserting a lubricant-free stopper into a lubricant-free barrel or lubricant-free cartridge tube in a manner that reduces the possibility of drug contamination and minimizes damage to the stopper. Summary of the Invention
[0006] According to one embodiment ("Embodiment 1"), a method for inserting a lubricant-free stop into a lubricant-free barrel includes: (A) inserting a stop including at least one sealing rib into a placement region located at a proximal end of an insertion tube, where the insertion tube has a body connected to the placement region via a transition zone; (B) lowering the body of the insertion tube into a syringe barrel having a barrel flange beyond the location of the barrel flange; (C) using an insertion pin to move the stop into a distal opening of the insertion tube; (D) retracting the insertion tube while the stop remains in a fixed position in the syringe barrel by the insertion pin and the stop is securely positioned in the syringe barrel; and (E) fully retracting the insertion pin and insertion tube from the barrel to form a syringe with a stop. At least the stop, the insertion tube, the body of the insertion tube, the syringe barrel, the barrel flange, and the insertion pin are free or substantially free of lubricant.
[0007] According to another embodiment ("embodiment 2") in addition to embodiment 1, the insertion tube has an average surface roughness (S a ).
[0008] According to another embodiment ("embodiment 3") in addition to embodiments 1 and 2, the body of the insertion tube has an average kurtosis (S ku ).
[0009] According to another embodiment ("Embodiment 4") that is additional to any of the preceding embodiments, the fastener is inserted into the insertion tube with a peak insertion force in the range of about 10N to about 200N.
[0010] According to another embodiment ("Embodiment 5") in addition to any of the preceding embodiments, the stop includes at least one sealing rib, the sealing rib having a line count of less than 30.
[0011] According to another embodiment ("embodiment 6") in addition to any of the preceding embodiments, the stoppered syringe has a 6 x 10 -6 It has a helium leak rate lower than that of SCCS.
[0012] According to another aspect ("Aspect 7") in addition to any of the preceding aspects, step (A) and step (B) occur sequentially or simultaneously.
[0013] According to another aspect ("Aspect 8") additional to any of the preceding aspects, in step (B), a gap is disposed between the insertion tube and the inner surface of the barrel to allow pressure relief.
[0014] According to another aspect ("Aspect 9"), additional to any of the aspects described above, in step (D), the insertion tube is retracted past the insertion pin.
[0015] According to another aspect ("Aspect 10"), additional to any of the aspects described above, in step (E), the insertion tube and the insertion pin are retracted sequentially or simultaneously.
[0016] According to another embodiment ("embodiment 11") in addition to any of the preceding embodiments, the stop includes an elastomeric body and a polymeric layer thereon.
[0017] According to another embodiment ("embodiment 12") additional to embodiment 11, the expanded fluoropolymer comprises an expanded fluoropolymer.
[0018] According to another embodiment ("embodiment 13") additional to embodiment 12, the expanded fluoropolymer comprises expanded polytetrafluoroethylene.
[0019] According to another embodiment ("embodiment 14") additional to any of the preceding embodiments, the therapeutic compound is delivered to the syringe barrel prior to lowering the insertion tube into the syringe barrel.
[0020] According to another embodiment ("embodiment 15") in addition to any of the preceding embodiments, the therapeutic agent comprises therein a biological compound, a therapeutic compound, or a combination thereof.
[0021] According to another embodiment ("Embodiment 16") additional to any of the preceding embodiments, the amount of particles in the barrel is less than about 600 particles / mL for particles greater than 10 μm in size, as measured in water for injection (WFI).
[0022] According to another embodiment ("Embodiment 17") additional to any of the preceding embodiments, the amount of particles in the barrel is less than 60 particles / mL for particles greater than 25 μm in size, as measured in water for injection (WFI).
[0023] According to another aspect ("Aspect 18"), in addition to any of the preceding aspects, the insertion tube is electropolished, extrusion horned, or a combination thereof.
[0024] According to another embodiment ("Embodiment 19"), a system includes: (A) an insertion tube having (1) a placement region having a diameter for receiving a stop from a stop feeder, (2) a body having a diameter smaller than the diameter of the placement region, and (3) a transition zone having a taper angle for transitioning the stop from the placement region to the insertion tube body, (B) an insertion pin for manipulating the stop through the insertion tube, and (C) a barrel having an inner surface for receiving the stop from the insertion tube and the therapeutic substance from the therapeutic feeder. (A)-(C) include a system for forming a pre-filled syringe or pre-filled cartridge, wherein the system, the pre-filled syringe, and the pre-filled cartridge are lubricant-free or substantially lubricant-free.
[0025] According to another embodiment ("embodiment 20") additional to embodiment 19, the taper angle is between about 1 degree and about 20 degrees.
[0026] According to another embodiment ("embodiment 21") in addition to embodiments 19 and 20, the insertion tube has an average surface roughness (S a ).
[0027] According to another embodiment ("embodiment 22") in addition to embodiments 19 to 21, the insertion tube body has an average kurtosis (S ku ).
[0028] According to another embodiment ("embodiment 23") in addition to embodiments 19-22, the insertion tube is electropolished, extrusion horned, or a combination thereof.
[0029] According to another embodiment ("embodiment 24") in addition to embodiments 19-23, the therapeutic agent comprises therein a biological compound, a therapeutic compound, or a combination thereof.
[0030] According to another embodiment ("embodiment 25"), in addition to embodiments 19-24, the stop includes an elastomeric body and a polymeric layer at least partially covering the elastomeric body.
[0031] According to another embodiment ("embodiment 26") additional to embodiment 25, the polymer layer comprises an expanded fluoropolymer.
[0032] According to another embodiment ("embodiment 27") additional to embodiment 26, the expanded fluoropolymer comprises expanded polytetrafluoroethylene.
[0033] According to another embodiment ("Embodiment 28"), a method for inserting a lubricant-free stop into a lubricant-free cartridge tube includes (A) inserting a stop including at least one sealing rib into a placement region located at a proximal end of an insertion tube, where the insertion tube has a body connected to the placement region via a transition zone, (B) lowering the body of the insertion tube into a cartridge tube having an end to a position located beyond the top of the cartridge tube, (C) moving the stop into a distal opening of the insertion tube using an insertion pin, (D) retracting the insertion tube while the stop remains in a fixed position in the cartridge tube by the insertion pin and the stop is securely positioned in the cartridge tube, and (E) fully retracting the insertion pin and insertion tube from the cartridge tube to form a cartridge with the stop. At least the stop, the insertion tube, the body of the insertion tube, the cartridge tube, the top of the cartridge tube, and the insertion pin are free or substantially free of lubricant.
[0034] According to another embodiment ("Embodiment 29") additional to embodiment 28, the fastener is inserted into the insertion tube with a peak insertion force ranging from about 10N to about 200N.
[0035] According to another embodiment ("embodiment 30"), in addition to embodiments 28 and 29, the stop includes at least one sealing rib, and the sealing rib has a line count of less than 30.
[0036] According to another embodiment ("embodiment 31") in addition to embodiments 28-30, (A) and step (B) occur sequentially or simultaneously.
[0037] According to another embodiment ("embodiment 32") in addition to embodiments 28-31, in step (B), a gap is disposed between the insertion tube and the inner surface of the cartridge tube to allow for pressure relief.
[0038] According to another aspect ("Aspect 33") in addition to Aspects 28 to 32, in step (D), the insertion tube is retracted beyond the insertion pin.
[0039] According to another aspect ("Aspect 34") in addition to Aspects 28 to 33, in step (E), the insertion tube and the insertion pin are retracted sequentially or simultaneously.
[0040] According to another embodiment ("embodiment 35"), in addition to embodiments 28-34, the stop includes an elastomeric body and a polymeric layer thereon.
[0041] According to another embodiment ("embodiment 36") additional to embodiment 35, the polymer layer comprises an expanded fluoropolymer.
[0042] According to another embodiment ("embodiment 37") additional to embodiment 36, the expanded fluoropolymer comprises expanded polytetrafluoroethylene.
[0043] According to another embodiment ("embodiment 38") in addition to embodiments 28-37, the method further includes delivering a therapeutic compound to the cartridge tube prior to lowering the insertion tube into the cartridge tube.
[0044] According to another embodiment ("embodiment 39") additional to embodiment 38, the therapeutic agent comprises a biological agent, a therapeutic compound, or a combination thereof therein.
[0045] According to another embodiment ("embodiment 40") in addition to embodiments 28-39, the insertion tube is electropolished, extrusion horned, or a combination thereof.
[0046] According to another embodiment ("embodiment 41") in addition to embodiments 28 to 40, the insertion tube has an average surface roughness (S a ).
[0047] According to another embodiment ("embodiment 42") in addition to embodiments 28-41, the body of the insertion tube has an average kurtosis (S ku ).
[0048] According to another embodiment ("embodiment 43") in addition to embodiments 28 to 42, the syringe with a stopper has a capacity of 6 x 10 -6 It has a helium leak rate lower than that of SCCS. [Brief description of the drawings]
[0049] The accompanying drawings are included to provide a further understanding of the disclosure, and are incorporated in and constitute a part of this specification, illustrating embodiments and, together with the description, serve to explain the principles of the disclosure.
[0050] [Figure 1A] FIG. 1A is a schematic diagram of a syringe according to some embodiments.
[0051] [Figure 1B] FIG. 1B is a schematic diagram of a cartridge according to some embodiments.
[0052] [Diagram 2] FIG. 2 is a schematic diagram showing the headspace between the stopper and the liquid in a barrel or cartridge tube, according to some embodiments.
[0053] [Diagram 3] FIG. 3 is a cutaway schematic of a stop having a polymer layer thereon, according to some embodiments.
[0054] [Figure 4] FIG. 4 is a cutaway schematic view of a stop having a laminate thereon, according to some embodiments.
[0055] [Figure 5A] FIG. 5A is an isometric view of an insertion tube according to some embodiments.
[0056] [Figure 5B] FIG. 5B is a cross-sectional view of the insertion tube of FIG. 5A.
[0057] [Figure 6A] FIG. 6A is an isometric view of an insertion pin according to some embodiments.
[0058] [Figure 6B] FIG. 6B is a cross-sectional view of the insertion pin of FIG. 6A.
[0059] [Figure 6C] FIG. 6C is a cross-sectional view of another insertion pin according to some embodiments.
[0060] [Figure 7A-E] 7A-7E show an exemplary insertion method utilizing an insertion tube in conjunction with an insertion pin to insert a lubricant-free stop into a lubricant-free syringe barrel, according to some embodiments.
[0061] [Figure 8A-E] 8A-E show an exemplary insertion method utilizing an insertion tube in conjunction with an insertion pin to insert a lubricant-free stop into a lubricant-free cartridge tube, according to some embodiments.
[0062] [Figure 9] FIG. 9 shows a system for assembling lubricant-free pre-filled syringes or cartridges. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0063] Those skilled in the art will readily appreciate that the various aspects of the present disclosure may be implemented by any number of methods and devices configured to perform the intended functions. It should also be noted that the accompanying drawings referenced herein are not necessarily drawn to scale and may be exaggerated to illustrate the various aspects of the present disclosure, and in that regard, the drawings should not be construed as limiting. The terms "barrel" and "syringe barrel" may be used interchangeably herein. It should be understood that the terms "lubricant-free" and "lubricant-free" may be used interchangeably herein. It should be noted that the phrases "non-lubricated syringe barrel" and "non-lubricated barrel" may be interchangeable with the phrase "non-lubricated cartridge tube" within this disclosure.
[0064] The present disclosure relates to a method of inserting a stop having a polymer layer (e.g., an expanded fluoropolymer layer) thereon into a lubricant-free barrel or lubricant-free cartridge tube by using an insertion tube and an insertion pin. The stop further comprises an elastomeric body and a polymer layer at least partially covering the elastomeric body. The syringe or cartridge may be pre-filled to store and deliver a drug or biological substance to a patient. As used herein, the term "syringe" or "cartridge" is meant to refer to any device that delivers at least one therapeutic compound (e.g., a drug or biological) via injection with a needle or a "needle-free" system (e.g., a Luer system). The syringe or cartridge may be used to administer different therapeutic compounds such as, for example, drugs and biologicals, including but not limited to, antibodies, antisense, RNA interference, gene therapy, primary and embryonic stem cells, vaccines, and combinations thereof. The following disclosure applies equally to the syringe or cartridge. Many types of medical delivery devices are contemplated and are considered to be within the scope of the present disclosure, such as, for example, a syringe, an auto-injector, or an injector pen.
[0065] As shown in FIG. 1A, the syringe 10 can include a barrel 20 having an inner surface 25 and a piercing element (e.g., needle) 30 for injecting a therapeutic compound. A plunger 50 is formed from a stop 40 that can be fixed to the end of a plunger rod 85. In some embodiments, the stop is not attached to the plunger rod 85. The stop 40 contacts at least a portion of the inner surface 25 of the barrel 20 via one or more ribs 42, 44. Although two ribs 42, 44 are shown in FIG. 1A, any number of ribs may be present on the stop 40, as long as there is at least one sealing rib, such as the front sealing rib 42. In this embodiment, the rib 44 may also be a sealing rib. In the following, for ease of explanation, both ribs 42, 44 will be referred to as sealing ribs. The sealing ribs provide the integrity of the container closure to the pre-filled syringe or cartridge. One or more flanges 70 can be used as finger grips to push and move the plunger 50 within the barrel 20. In some embodiments, the stopper 40 includes opposing proximal and distal ends 90 and 95 and a side surface 115 extending therebetween. The side surface 115 of the stopper 40 may include one or more sealing ribs, such as one or more circumferentially extending annular ribs. Referring to FIG. 1B, in the cartridge 35, the plunger rod (not shown) and the stopper 40 are unattached. The stopper 40 contacts at least a portion of the inner surface 25 of the cartridge tube 32 via one or more ribs, such as the sealing rib 42. Additionally, the needle (not shown) is separate from the cartridge tube 32. The cartridge 35 includes a sealed cap 34, rather than a needle. It should be understood that the components of the syringe 10 and the cartridge 35 are free of lubricants or are substantially free of lubricants.
[0066] Referring to FIG. 2, in some embodiments, the stop 40 is inserted into a specific desired location within the barrel 20. The term "barrel 20" may be interchanged herein with "cartridge tube 32." This specific location is a predetermined height above the liquid level 60 of the therapeutic solution 55 within the barrel 20. The therapeutic solution 55 may have a liquid height H1. H1 is a function of the amount of therapeutic solution 55 located within the barrel 20, which in turn depends on the volume of the therapeutic substance to be administered. In some embodiments, the location of the stop 40 within the barrel allows for a specific amount of "headspace" H2. As used herein, "headspace" is meant to represent the height from the top of the liquid level 60 to the tip 45 of the forward sealing rib 42 of the stop 40. The sealing rib 44 is shown for illustrative purposes only. In some embodiments, the headspace H2 is minimized to reduce the amount of air within the barrel 20 that may be injected into the patient for drug stability and / or for delivery purposes.
[0067] In some embodiments, after inserting fastener 40 using the methods described herein, headspace height H2 is less than about 25 mm, less than about 23 mm, less than about 21 mm, less than about 19 mm, less than about 17 mm, less than about 15 mm, less than about 13 mm, less than about 10 mm, less than about 8 mm, less than about 5 mm, less than about 3 mm, less than about 2 mm, less than about 1 mm, or less than about 0.5 mm. In some embodiments, headspace H2 can be in the range of about 1 mm to about 25 mm, about 1 mm to about 23 mm, about 1 mm to about 21 mm, about 1 mm to about 19 mm, about 1 mm to about 17 mm, about 1 mm to about 15 mm, about 1 mm to about 13 mm, about 1 mm to about 10 mm, about 1 mm to about 8 mm, about 1 mm to about 5 mm, about 1 mm to about 3 mm, about 1 mm to about 2 mm, about 0.5 mm to about 2 mm, or about 0.5 mm to about 1 mm.
[0068] The barrel 20 or cartridge tube 32 may be formed from a rigid material, such as a glass material (e.g., borosilicate glass), a ceramic material, one or more polymeric materials (e.g., polypropylene, polyethylene, and copolymers thereof), a metallic material, a plastic material (e.g., cyclic olefin polymers and cyclic olefin copolymers), and combinations thereof. In certain embodiments, the barrel 20 or cartridge tube 32 may be formed of glass, resin, plastic, or metal without a lubricant (e.g., silicone) present on the inner surface 25 of the barrel 20 or cartridge tube 32.
[0069] The stop 40 is formed from an elastomeric body at least partially covered by a polymer (e.g., an expanded polymer). In some embodiments, the elastomeric body may have one or more polymer or expanded polymer layers thereon. For example, FIG. 3 shows a stop 40 having an elastomeric body 125 and a single layer of a polymer or expanded polymer 140 at least partially covering the elastomeric body 125. In another embodiment shown in FIG. 4, the stop 40 includes an elastomeric body 125 and a laminate layer 130 formed from a polymer or expanded polymer 140 (e.g., an expanded fluoropolymer) and a porous layer 150 (e.g., fluorinated ethylene propylene (FEP)). As discussed above, the stop 40 may have one or more sealing ribs, such as sealing ribs 42, 44, extending therefrom.
[0070] In some embodiments, the expanded polymer is an expanded fluoropolymer. Examples of fluoropolymers that can be used as the polymer or expanded polymer 140 or as the porous layer 150 include, but are not limited to, polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), densified expanded polytetrafluoroethylene (ePTFE), densified polytetrafluoroethylene (PTFE), expanded modified PTFE, expanded copolymers of PTFE, ethylene-(perfluoroethylene-propene) copolymers (EFEP), polyvinylidene fluoride (PVDF), fluorinated ethylene propylene (FEP), perfluoroalkoxy copolymer resins (PFA), polyvinyl fluoride, perfluoropropyl vinyl ether, and perfluoroalkoxy polymers. Blends of PTFE, expandable modified PTFE, and expandable copolymers of PTFE are disclosed in, for example, but not limited to, U.S. Patent No. 5,708,044 to Branca, U.S. Patent No. 6,541,589 to Baillie, U.S. Patent No. 7,531,611 to Sabol et al., U.S. Patent No. 8,637,144 to Ford, and U.S. Patent No. 9,139,669 to Xu et al. Non-fluoropolymers such as polyethylene, polypropylene, and polycarbonate may also be utilized as the polymer or expanded polymer layer 140.
[0071] Non-limiting examples of elastomers that can be used to form the elastomeric body 125 include any elastomer suitable for the application, most notably rubbers comprised of butyl, bromobutyl, chlorobutyl, silicone, nitrile, styrene butadiene, polychloroprene, ethylene propylene diene, fluoroelastomers, thermoplastic elastomers (TPEs), thermoplastic vulcanizates (TPVs), and combinations and blends thereof. In some embodiments, the elastomeric body 125 can have an initial modulus in the range of about 2.5 MPa to about 5 MPa. In some embodiments, the elastomeric body 125 can have an initial modulus of about 3 MPa to about 4 MPa. In one non-limiting embodiment, the initial modulus can be, for example, about 3.5 MPa.
[0072] The laminate layer 130 can have a thickness of less than about 30 microns. In some embodiments, the thickness of the laminate layer 130 can range from about 0.5 microns to about 20 microns. The films forming the polymer or oriented polymer layer 140 (FIG. 3) and / or the porous layer 150 (FIG. 4) can be pre-treated or post-treated with chemical etching, plasma treatment, corona treatment, roughening, etc. to improve bonding of the polymer or oriented polymer layer 140 and / or the porous layer 150 to the elastomeric body 125. The materials of the laminate layer 130 and the polymer or oriented polymer layer 140 are selected to provide low coefficient of friction, compliance, low extractables and leachables, good barrier properties related to extractables and leachables from the elastomeric body 125, and good air and liquid impermeability.
[0073] In another embodiment, the polymer or oriented polymer layer 140 may be used with non-elastomeric materials, such as, but not limited to, plastics (e.g., polypropylene, polycarbonate, and polyethylene), thermoplastics, and fluoropolymer materials (e.g., ethylene-(perfluoro-ethylene-propene) copolymer (EFEP), polyvinylidene fluoride (PVDF), and perfluoroalkoxy polymer resins (PFA)).
[0074] In some embodiments, the insertion tube and insertion pin can be used in combination to insert a non-lubricated stop into a non-lubricated syringe barrel or non-lubricated cartridge tube 32 with little or no distortion, buckling, or wrinkling of the stop. Referring to FIGS. 5A and 5B, an exemplary insertion tube 1000 is shown. The insertion tube 1000 allows a non-lubricated stop to be placed into a non-lubricated syringe barrel or non-lubricated cartridge tube without over-pressurizing the liquid contained therein. As shown in FIGS. 5A and 5B, the insertion tube 1000 has a proximal end 1012 and a distal end 1014. The insertion tube 1000 also includes a body 1010 and a device adaptor 1020. An alignment flange 1030 protrudes from the tip of the device adaptor 1020. The alignment flange 1030 has a shape sufficient to align with an auxiliary device on a conventional syringe fill line (not shown). The body 1010 is the portion of the insertion tube 1000 that fits into the syringe barrel and allows the stop to be placed into the syringe barrel or cartridge tube. The outer diameter D1 of the body 1010 is sized smaller than the inner diameter of the syringe barrel or cartridge tube to allow for an air space between the outside of the insertion tube body 1010 and the syringe barrel or cartridge tube during insertion (as shown in FIGS. 7C and 8C ).
[0075] The transition zone 1040 is where the stop is compressed to a diameter D2 sufficient to pass through the distal opening 1050 of the insertion tube 1000. Thus, the diameter of the stop (not shown) decreases from D3 (i.e., the diameter of the placement region 1042) to D2 (i.e., the diameter at the distal end of the transition zone 1040). The transition zone 1040 tapers from the placement region 1042 to the body 1010 at a taper angle (B). The placement region 1042 has a diameter D3 of about 3 mm to about 20 mm, about 5 mm to about 15 mm, about 7 mm to about 10 mm, about 7 mm to about 8 mm, or about 7.5 mm to about 8 mm. The taper angle (B) may be in the range of about 1 degree to about 20 degrees, about 5 degrees to about 20 degrees, about 1 degree to about 15 degrees, about 2 degrees to about 15 degrees, about 3 degrees to about 15 degrees, about 4 degrees to about 15 degrees, about 5 degrees to about 15 degrees, about 1 degree to about 10 degrees, or about 5 degrees to about 10 degrees.
[0076] 6A, 6B, and 6C show an insertion pin 600 (FIGS. 6A and B) and an insertion pin 605 (FIG. 6C) that can be used in combination with an insertion tube, such as the insertion tube 1000 shown in FIGS. 5A and 5B, to insert a stop into a barrel or cartridge tube. The insertion pins 600 and 605 include a cylindrical body 602 having a proximal end 606 and a distal end 608. A pin tip 610 of the insertion pin 600 is connected to the cylindrical body 602 and aligns with a cavity in a stop (not shown). The distal end 608 can be sized to mate with a mechanical adapter (not shown) that is used to push the insertion pins 600 and 605 through an insertion tube, such as the insertion tube 1000 shown in FIGS. 5A and 5B.
[0077] The cylindrical body 602 has a diameter D4 that is slightly smaller than the inner diameter D2 of the body of the insertion tube (e.g., diameter D2 of the insertion tube 1000 depicted in FIGS. 5A and 5B). The rounded surface 612 of the cylindrical body 602 is designed to push the distal end of the stop and provide straightness and stability while inserting the stop into the syringe barrel. The cylindrical body 602 has a diameter D4 that may range from about 2 mm to about 18 mm, including any and all subranges therebetween. In other embodiments, the rounded surface 612 may include or be formed with shapes other than a radius, such as, for example, having a flat portion, a linear taper (e.g., straight), curved, rounded, or multiple tapers. In at least one other embodiment, a stop without an internal cavity may be used, and the insertion pin may even be modified to reduce or eliminate the pin tip, as shown in FIG. 6C. As shown in FIG. 6C, the insertion pin 605 does not have a pin tip, but instead is formed from a flat or substantially flat surface 614.
[0078] Returning to Figures 6A and 6B, the pin tip 610 has a length (L) that is approximately equal to the depth of the fastener's internal cavity. In some embodiments, the pin tip 610 has a length of about 3 mm to about 8 mm, about 4 mm to about 7 mm, about 4.5 mm to about 5.5 mm, or about 5 mm to about 6 mm. In addition, the pin tip 610 may have a width (W) that may be approximately the same as the width of the fastener's internal cavity. In some embodiments, the pin tip 610 has a width of about 0.5 mm to about 5 mm, about 1 mm to about 4 mm, about 1 mm to about 3 mm, about 2 mm to about 3 mm, about 1.5 mm to about 2.5 mm, about 3 mm to about 6 mm, about 5 mm to about 9 mm, or about 8 mm to about 11 mm. The combination of the width (W) and length (L) of the pin tip 610 creates a volume that matches the fastener's cavity during insertion. 6A and 6B, the tip 610 has a rounded end. The fastener 40 can be inserted into the insertion tube 1000 with a peak insertion force ranging from about 10N to about 200N, about 20N to about 100N, about 30N to about 80N, about 40N to about 60N, or about 40N to about 60N. In some embodiments, the peak insertion force is greater than zero but less than about 50N, greater than zero but less than about 40N, greater than zero but less than about 30N, or greater than zero but less than about 20N.
[0079] The insertion pins 600 and 605 may be formed from a polymeric material, such as polyetheretherketone (PEEK), polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), or a metallic material, such as stainless steel, or a combination thereof.
[0080] 7A-7E and 8A-8E, a cross-section of a method for inserting a non-lubricated stop, at least partially covered with a polymer or oriented polymer layer or laminate layer, into a non-lubricated syringe barrel (FIGS. 7A-7E) or a non-lubricated cartridge tube (FIGS. 8A-8E) is shown in a series of steps. Note that the tip cap 27 for the barrel 20 is shown in FIGS. 7A-7E for illustrative purposes only. In FIGS. 7A-7E and 8A-8E, an insertion rod 650 is shown that includes both an insertion pin 600 (FIGS. 7A-7E) or an insertion pin 605 (FIGS. 8A-8E) and a mechanical adapter 620. First, as shown in FIG. 7A, a stop 40 having a cavity 48 is placed into a placement area 1042 located at a proximal end 1012 of an insertion tube 1000. The distal end of the insertion tube 1000 is generally indicated by reference numeral 1014. The insertion tube 1000 is positioned over and aligned with the inner surface 25 of the syringe barrel 20. In some embodiments, the syringe barrel 20 is already filled with the treatment solution 55. In FIG. 8A, a solid stop 40 (i.e., no cavity therein) is positioned in a positioning area 1042 located at a proximal end 1012 of the insertion tube 1000. The distal end of the insertion tube 1000 is generally indicated by reference numeral 1014. The insertion tube 1000 is positioned over and aligned with the inner surface 25 of the cartridge tube 32. In some embodiments, the cartridge tube 32 is already filled with the treatment solution 55. Looking at FIGS. 7B and 8B, the body 1010 of the insertion tube 1000 is then lowered in the direction of arrow A1 into the interior space of the syringe barrel 20 or cartridge tube 32, respectively, without contacting the inner surface 25 of the syringe barrel 20 (FIG. 7B) or cartridge tube 32 (FIG. 8B). It should be understood that a gap is located between the insertion tube 1000 and the inner surface 25 of the barrel 20 or cartridge tube 32 to allow for pressure relief. Additionally, the steps shown and described in Figures 7A and 7B, and Figures 8A and 8B, may occur sequentially or simultaneously, as described above.
[0081] The body 1010 of the insertion tube 1000 is moved until it passes the barrel flange 70 (FIG. 8B) or end portion 36 (FIG. 8B) of the cartridge tube 32 and is stopped when the distal opening 1050 of the insertion tube 1000 is located at a specific position that determines the final position of the stop 40 relative to the surface of the liquid therapeutic solution 55. As shown in FIGS. 7C and 8C, the insertion rod 650 is then used to move the stop 40 in the direction of arrow A2 through the length of the insertion tube 1000 and through the transition region 1040 until it reaches the distal opening 1050 of the insertion tube 1000. It should be understood that the position of the sealing rib of the stop 40 within the insertion tube 1000 should be properly positioned when the stop 40 is located at the distal opening 1050. For example, if the stop 40 is positioned too far from the distal opening 1050 of the insertion tube 1000, the stop 40 may be inaccurately positioned within the barrel 20 (FIG. 7C) or cartridge tube 32 (FIG. 8C) when the insertion tube 1000 is retracted. Alternatively, if the stop 40 is over-inserted through the insertion tube 1000 such that one or more sealing ribs protrude from the distal opening 1050 of the insertion tube 1000, the headspace H2 above the treatment solution 55 may be pressurized during the insertion process. With reference to FIGS. 7D and 8D, the insertion rod 650 holds the stop 40 in place while the insertion tube 1000 is retracted in the direction of arrow A3 until the stop 40 exits the distal opening 1050 of the insertion tube 1000. As a result, the stop 40 is positioned within the barrel 20 (FIG. 7D) or cartridge tube 32 (FIG. 8D) to create the desired final headspace H2. 7E and 8E, the insertion rod 650 and insertion tube 1000 have been fully retracted in the direction of arrow A4 from the barrel 20 (FIG. 7E) or cartridge tube 32 (FIG. 8E) and stop 40. It should be understood that all methods of inserting a lubricant-free stop into a syringe barrel or cartridge tube are performed without a lubricant (such as, but not limited to, silicone or silicone oil), including the attachment devices (e.g., insertion pin, insertion tube, etc.).
[0082] An example of a system 800 for assembling a pre-filled syringe or cartridge is shown in FIG. 9. The system includes a stop feeder 810 for providing a silicone-free stop and a treatment feeder 850 for providing an active therapeutic agent of interest to the pre-filled syringe or cartridge. The system also includes an insertion tube 801 having a placement region 820 and a body 840 having a smaller diameter than the placement region 820, and a transition zone 830 having an angle of 1°-20° that reduces the insertion diameter of the silicone-free stop from the placement diameter 820 to the diameter of the body 840. The system also includes at least one syringe barrel or cartridge tube 870 (or alternatively, an array of syringe barrels or cartridge tubes) arranged to receive the insertion tube 801. The system also includes an insertion rod 860 for manipulating a stop in the insertion tube 801, the manipulation step being step D. The system further includes a mechanism for lowering insertion tube 801 into syringe barrel 870 in process step B or removing insertion tube 801 from syringe barrel 870 in process step E. In step C, a stop without lubricant is placed in placement area 820.
[0083] In one embodiment, in step A, an active therapeutic agent is fed into a silicone-free syringe barrel or cartridge tube. Sequentially or simultaneously, in step C, a stop (not shown) is removed from the stop feeder 801 and placed in the placement area 820. In step B, the insertion tube 801 is lowered into the syringe barrel or cartridge tube 870. The stop is then manipulated down to the distal end of the body 840 in step D, but does not yet leave the insertion tube 801. In the next step E, the insertion rod 860 holds the stop in a fixed position a sufficient distance to deploy the stop into the barrel or cartridge tube while the insertion tube is housed within the barrel or cartridge tube. Finally, in step F, the insertion rod 860 and insertion tube 801 are retracted away from the stop. It should be noted that the insertion rod 860 and insertion tube 801 can be removed from the barrel or cartridge tube 870 sequentially or simultaneously.
[0084] In some embodiments, the insertion of the stop into the syringe barrel 20 or cartridge tube 32 is considered successful if, after insertion of the stop 40 into one or more of the syringe barrel 20, cartridge tube 32, or insertion tube 1000, there are less than 10 lines formed (e.g., grooved or etched) on the front sealing rib 42 of the stop 40. The front sealing rib is the rib closest to the stop location. The lines are visible using 100x magnification with an optical microscope (such as a Keyence VHX-5000). In some implementations, the front sealing rib of the stop can have 1 to 20 lines, 1 to 15 lines, 5 to 10 lines, 1 to 5 lines, or 1 to 3 lines. In exemplary embodiments, the stop does not have more than 30 lines due to the increased likelihood of syringe failure. In some embodiments, there may be no lines on the front sealing rib of the stop. Although not shown, this "line count" methodology is similarly applicable to determining the quality of an insertion tube, syringe barrel, or other component where a stop is moved to its final location (i.e., insertion point). In some embodiments, the interior surface of the body of the insertion tube produces fewer than 30 lines (e.g., 1-30 lines) when measured over any rib (e.g., the front sealing rib of the stop) that contacts the barrel or cartridge. If there are fewer than 30 lines, the stop seal is unlikely to fail. Advantageously, there are 25 or fewer lines (e.g., 1-25 lines), 20 or fewer lines (e.g., 1-20 lines), 15 or fewer lines (e.g., 1-15 lines), 10 or fewer lines (e.g., 1-10 lines), 5 or fewer lines (e.g., 1-5 lines), or 3 or fewer lines (e.g., 1-3 lines).
[0085] In addition, the helium leak rate of the stopper syringe or cartridge is 1 x 10 -8 Less than sccs or 1×10 -7 The stop is considered to have been successfully inserted into the barrel or cartridge tube if the helium leak rate is less than 6×10 -6sccs or less. The helium leak rate can be determined according to the method described in U.S. Patent No. 10,471,211 to Rusch et al., and the helium leak rate and results are described in Example 1 below. It should be understood that the helium leak rate can be used in the same manner as the "line count" method (described above) to determine the quality of an insertion tube, syringe barrel, cartridge tube, or other component where a stop is moved to its insertion point.
[0086] In some embodiments, successful insertion (as defined by helium leak rate and / or line count) of a lubricant-free stop into a lubricant-free syringe barrel or lubricant-free cartridge tube is determined by the average surface roughness (S a ) and / or the average kurtosis of the inner surface of the insertion tube (S ku This can be achieved by modifying the target average surface roughness (S a ) and / or the target mean kurtosis (S ku ) can be achieved by a variety of methods known to those skilled in the art, including but not limited to electropolishing, extrusion honing, or a combination thereof. a ) and mean kurtosis (S ku The test method and results of this are described in Example 1.
[0087] In some embodiments, the insertion tube has an average surface roughness (S a In some embodiments, the surface roughness may be an average surface roughness (S a In addition, the insertion tube has a mean kurtosis (S ku ) can be obtained. a ) and / or mean kurtosis (S ku) are combined to define the space required for proper insertion of the stopper for each shape of the insertion tube.
[0088] At a minimum, the syringe barrel and stop (e.g., syringe component), or cartridge tube and stop (e.g., chemical artridge component), vent tube, and insertion pin are "lubricant-free" or "substantially lubricant-free." As used herein, the term "lubricant-free" is meant to indicate the absence of any type of lubricant, either intentionally or accidentally, added to the syringe barrel, cartridge tube, stop, and / or any equipment for manufacturing them. Any amount of lubricant that may be present is present only in trace amounts (i.e., undetectable by any known measuring device or method). However, in some embodiments, lubricant may be inadvertently added by improper handling or residual lubricant on the manufacturing equipment, so long as such lubricant is not intentionally added and is present only in trace amounts. It is understood that the needle of the syringe barrel intentionally has lubricant thereon to facilitate insertion into a patient. However, the needle is not considered to be within the scope of this disclosure.
[0089] The term "substantially free of lubricant" means that there may be a detectable amount of lubricant by any known measurement device or method. This means that in some embodiments, there may be about 0 μg to about 5 μg, about 1 μg to about 5 μg, or about 2 μg to about 5 μg of lubricant on the inner surface of the syringe. The absence or substantial absence of lubricant may be measured using gas chromatography (GC) mass spectrometry or inductively coupled plasma (ICP) mass spectrometry. Substantially free of lubricant may also, or alternatively, be measured by the amount of particles in the syringe barrel, measured in water for injection (WFI), after the WFI is exposed to the fully assembled syringe (e.g., glass barrel and stopper, and alternatively at least one therapeutic compound). In some embodiments, the amount of particles in the barrel may be less than about 600 particles / mL for particles greater than 10 μm in size, or less than 60 particles / mL for particles greater than 25 μm in size, as measured in WFI.
[0090] In some embodiments, lubricants other than silicone-based lubricants may be acceptable. Common silicone-based lubricants include silicone oil or silicone grease, siloxane, polysiloxane, organosiloxane, polyorganosiloxane, silicate ester, and similar compounds and combinations thereof. In other embodiments, water-based lubricants (e.g., polyethylene glycol, glycerin, cellulose ether), oil-based lubricants (e.g., petroleum jelly, paraffin, and olefin), and combinations thereof may be present on the inner surface of the syringe barrel or cartridge tube. In further embodiments, the inner surface of the syringe barrel or cartridge tube may be free of any type of lubricant, but the syringe barrel or cartridge tube may have a finish or polish.
[0091] It should be understood that the ranges described herein may be utilized with 0.5 mL to 20 mL syringes or cartridges, but may be appropriately scaled to smaller or larger syringes or cartridges. It should also be understood that one or more design features of the syringes described herein may be combined with other features of the other syringes and cartridges described herein.
[0092] In another aspect, the syringe barrels, cartridge tubes, plunger rods, and stops described herein may be used in combination with different therapeutic compounds, such as, for example, drugs and biologics. Such therapeutic compounds include, but are not limited to, antibodies, antisense, RNA interference, gene therapy, primary and embryonic stem cells, vaccines, and combinations thereof. For example, the embodiments described herein may be utilized in combination with any or all of the following biologics and / or therapeutic compounds:
[0093] Cell therapy employs cells that are derived from the endoderm (e.g., exocrine epithelial cells and hormone-secreting cells), cells that are derived from the ectoderm (e.g., keratinized epithelial cells, moist stratified barrier epithelial cells, sensory transducer cells, autonomic nerve cells, sensory organs and peripheral neuron supporting cells, central nervous system nerve and glial cells, lens cells), cells that are derived primarily from the mesoderm (e.g., metabolic and storage cells, barrier function cells (lung, intestine, exocrine glands, and urogenital tract)), extracellular matrix cells, contractile cells, blood and immune cells, germ cells, nurse cells, interstitial cells, or combinations thereof. Cells that have been genetically, chemically, or physically altered or modified are also considered within the scope of this disclosure.
[0094] Exocrine epithelial cells include, but are not limited to, salivary gland mucous cells, salivary gland #1, von Ebner's gland cells of the tongue, mammary gland cells, lacrimal gland cells, canal gland cells of the ear, eccrine gland dark cells, eccrine gland clear cells, apocrine gland cells, cilia gland cells of the eyelid, sebaceous gland cells, Hohmann's gland cells of the nose, Brunner's gland cells of the duodenum, seminal vesicle cells, prostatic cells, bulbourethral gland cells, Bartholin's gland cells, urethral gland cells, endometrial cells, isolated goblet cells of the respiratory and gastrointestinal tract, gastric mucosal cells, gastric gland zymogen cells, gastric gland acid secreting cells, pancreatic acinar cells, Paneth cells of the small intestine, type II pneumocytes of the lung, and Clara cells of the lung. Hormone secreting cells include, but are not limited to, anterior pituitary cells, intermediate pituitary cells, large neurosecretory neuronal cells, cells of the digestive and respiratory tracts, thyroid cells, parathyroid cells, adrenal cortex cells, Leydig cells of the testes which secrete testosterone, inner thecal cells of the ovarian follicles which secrete estrogen, luteal cells of ruptured follicles which secrete progesterone, juxtaglomerular cells, macula densa cells of the kidney, circumpolar cells of the kidney, mesangial cells of the kidney, and islet cells of the pancreas. Keratinizing epithelial cells include, but are not limited to, epidermal keratinocytes, epidermal basal cells, fingernail and toenail keratinocytes, nail bed basal cells, medullary hair stem cells, cortical hair stem cells, cuticular hair stem cells, cuticular root sheath cells, root sheath cells of Huxley's layer, root sheath cells of Henle's layer, outer root sheath cells, and hair matrix cells. Wet stratified barrier epithelial cells include, but are not limited to, surface epithelial cells of stratified squamous and basal cells of the epithelium of the cornea, tongue, oral cavity, esophagus, anal canal, distal urethra, and vagina, urethral epithelial cells. Sensory transducer cells include, but are not limited to, inner hair cells of the organ of Corti, outer hair cells of the organ of Corti, basal cells of the olfactory epithelium, cold sense primary sensory neurons, heat sense primary sensory neurons, Merkel cells of the epidermis, olfactory receptor nerves, primary sensory neurons, photoreceptor cells of the retina of the eye, proprioceptive primary sensory neurons, touch primary sensory neurons, type I carotid body cells, type II carotid body cells, type I hair cells of the vestibular system of the ear, type II carotid body cells of the ear, type I taste bud cells. Autonomic nerve cells include, but are not limited to, cholinergic nerve cells, adrenergic nerve cells, peptidergic nerve cells.Sensory organ and peripheral neuron supporting cells include, but are not limited to, inner pillar cells of the organ of Corti, outer pillar cells of the organ of Corti, inner phalangeal cells of the organ of Corti, outer phalangeal cells of the organ of Corti, border cells of the organ of Corti, Hensen's cells of the organ of Corti, vestibular supporting cells, taste bud supporting cells, olfactory epithelium supporting cells, Schwann cells, satellite glial cells, enteric glial cells. Central nervous system neural and glial cells include, but are not limited to, astrocytes, neuronal cells, oligodendrocytes, and spindle neurons. Lens cells include, but are not limited to, anterior lens epithelial cells, and crystalline lens fiber cells. Metabolic and storage cells include, but are not limited to, adipocytes, and hepatic adipocytes. Barrier function cells include, but are not limited to, renal parietal cells, renal glomerular epithelial cells, renal proximal tubule brush border cells, cells of the thin segment of the loop of Henle, renal distal tubule cells, renal collecting duct cells, chief cells, interstitial cells, type I alveolar epithelial cells, pancreatic duct cells, smooth muscle duct cells, chief cells, interstitial cells, duct cells, intestinal brush border cells, exocrine gland striated duct cells, gallbladder epithelial cells, testicular efferent duct non-ciliated cells, epididymal chief cells, and epididymal basal cells. Extracellular matrix cells include, but are not limited to, ameloblasts, semilunar epithelial cells of the vestibular system of the ear, interdental epithelial cells of the organ of Corti, loose connective tissue fibroblasts, septal fibroblasts, tendon fibroblasts, bone marrow reticular connective tissue fibroblasts, other non-epithelial fibroblasts, pericytes, nucleus pulposus cells of the intervertebral disc, cementoblasts, odontoblasts, hyaline chondrocytes, fibrochondrocytes, elastic chondrocytes, osteoblasts, osteoprogenitor cells, vitreous cells of the vitreous body of the eye, perilymphatic space stellate cells of the ear, hepatic stellate cells, and pancreatic stellate cells. Contractile cells include, but are not limited to, skeletal muscle cells, satellite cells, cardiac muscle cells, smooth muscle cells, myoepithelial cells of the iris, and myoepithelial cells of the exocrine glands. Blood and immune cells include, but are not limited to, erythrocytes, megakaryocytes, monocytes, connective tissue macrophages, epithelial Langerhans cells, osteoclasts, dendritic cells, microglia, neutrophilic granulocytes, eosinophilic granulocytes, basophilic granulocytes, hybridoma cells, mast cells, helper T cells, suppressor T cells, cytotoxic T cells, natural killer T cells, B cells, natural killer cells, reticulocytes, stem cells and precursors involved in the blood and immune systems.Germ cells include, but are not limited to, oogonia / oocytes, spermatids, spermatocytes, spermatogonia, spermatozoa. Nurse cells include, but are not limited to, ovarian follicular cells, Sertoli cells, thymic epithelial cells. Stromal cells include, but are not limited to, stromal kidney cells, and combinations thereof.
[0095] Examples of antibodies, antisense, RNA interference, or gene therapy directed against protein targets or genes include Ataxia Telangiectasia Mutated, tumor protein p53, checkpoint kinase 2, breast cancer susceptibility protein, double strand break repair protein, DNA repair protein RAD50, Nibrin, p53 binding protein, mediator of DNA damage checkpoint protein, H2A histone family member X, microcephalin, C-terminal binding protein 1, chromosome integrity protein 1A; esterases; phosphatases. Ion channels include, but are not limited to, ligand-gated ion channels, voltage-gated ion channels. Growth factors include, but are not limited to, nerve growth factor (NGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), c-fos-induced growth factor (FIGF), platelet-activating factor (PAF), transforming growth factor beta (TGF-β), bone morphogenetic protein (BMP), activin, inhibin, fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), glial cell line-derived neurotrophic factor (GDNF), growth differentiation factor-9 (GDF9), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), growth factor (KGF), migration stimulating factor (MSF), hepatocyte growth factor-like protein (HGFLP), hepatocyte growth factor (HGF), hepatoma-derived growth factor (HDGF), insulin-like growth factor. G protein-coupled receptors (GPCRs) include, but are not limited to, the following: Adenosine receptor family, Adrenergic receptor family, Angiotensin II receptor, Apelin receptor, Vasopressin receptor family, Brain-specific angiogenesis inhibitor family, Bradykinin receptor family, Bombesin receptor family, Complement component 3a receptor 1, Complement component 5a receptor 1, Calcitonin receptor family, Calcitonin receptor-like family, Calcium-sensing receptor, Cholecystokinin A receptor (CCK1), Cholecystokinin B receptor (CCK2), Chemokine (CC motif) receptor family,Sphingosine-1-phosphate receptor family, succinate receptor, cholinergic receptor family. Chemokine-like receptor family, cannabinoid receptor family, corticotropin-releasing hormone receptor family, prostaglandin D2 receptor, chemokine C-X3-C receptor family, chemokine (CXC motif) receptor family, Burkitt's lymphoma receptor, chemokine (CXC motif) receptor family, cysteinyl leukotriene receptor 2 (CYSLT2), chemokine receptor (FY), dopamine receptor family, G protein-coupled receptor 183 (GPR183), lysophosphatidic acid receptor family family, endothelin receptor family, coagulation factor II (clotting) receptor family, free fatty acid receptor family, formyl peptide receptor family, follicle-stimulating hormone receptor (FSHR), gamma-aminobutyric acid (GABA) B receptor, galanin receptor family, glucagon receptor, growth hormone releasing hormone receptor (GHRH), ghrelin receptor (ghrelin), growth hormone secretagogue receptor 1b (GHSR1b), gastric inhibitory polypeptide receptor (GIP), glucagon-like peptide receptor family, gonadotropin releasing hormone Hormone receptor (GnRH), pyroglutamylated RF-amide peptide receptor (QRFPR), G protein-coupled bile acid receptor 1 (GPBA), hydroxycarboxylic acid receptor family, lysophosphatidic acid receptor 4 (LPA4) lysophosphatidic acid receptor 5 (GPR92), G protein-coupled receptor 79 pseudogene (GPR79), hydroxycarboxylic acid receptor 1 (HCA1), G protein-coupled receptor (C5L2, FFA4, FFA4, FFA4, FFA4, GPER, GPR1, GPR101, GPR107, GPR119, GPR12, GPR1 ... , GPR123, GPR132, GPR135, GPR139, GPR141, GPR142, GPR143, GPR146, GPR148, GPR149, GPR15, GPR150, GPR151, GPR152, GPR157, GPR161, GPR162 , GPR17, GPR171, GPR173, GPR176, GPR18, GPR182, GPR20, GPR22, GPR25, GPR26, GPR27, GPR3, GPR31, GPR32, GPR35, GPR37L1, GPR39, GPR4, GPR45,GPR50, GPR52, GPR55, GPR6, GPR61, GPR65, GPR75, GPR78, GPR83, GPR84, GPR85, GPR88, GPR97, TM7SF1), metabotropic glutamate receptor family, gastrin releasing peptide receptor (BB2), orexin receptor family, histamine receptor family, 5-hydroxytryptamine receptor family, KISS1-derived peptide receptor (kisspeptin), leucine-rich repeat-containing G protein-coupled receptor family, luteinizing hormone / chorionic gonadotropin LH receptor, leukotriene B4 receptor (BLT1), adenylate cyclase-activating polypeptide 1 receptor 1 (mPAC1), motilin receptor, melanocortin receptor family, melanin-concentrating hormone receptor 1 (MCH1), neuropeptide Y1 receptor (Y1), neuropeptide Y2 receptor (NPY2R), opioid receptor family, oxytocin receptor (OT), P2Y purinergic receptor 12 (mP2Y12), P2Y purinergic receptor 6 (P2Y6), pancreatic polypeptide receptor family, platelet-activating factor receptor family, prostaglandin receptor family, Randin E receptor family, prostanoid IP1 receptor (IP1), MAS-related GPR member family, rhodopsin (rhodopsin), relaxin family peptide receptor family, somatostatin receptor family, tachykinin receptor family, melatonin receptor family, urotensin receptor family, vasoactive intestinal peptide receptor 1 (mVPAC1), neuromedin B receptor (BB1), neuromedin U receptor 1 (NMU1), neuropeptide B / W receptor family, neuropeptide FF receptor 1 (NPFF1), Neuropeptide S receptor 1 (NPS receptor), neuropeptide Y receptor family, neurotensin receptor 1 (NTS1), opsin 5 (OPN5), opioid receptor-like receptor (NOP), oxoeicosanoid (OXE) receptor 1 (OXE), oxoglutarate (α-ketoglutarate) receptor 1 (OXGR1), purinergic receptor family, pyrimidinergic receptor family, prolactin-releasing hormone receptor (PRRP), prokineticin receptor family, platelet-activating receptor (PAF), prostaglandin F receptor family,Prostaglandin I2 (prostacyclin) receptor family, parathyroid hormone receptor family, muscarinic 4 (rM4), prostanoid DP2 receptor (rGPR44), prokineticin receptor family, relaxin family peptide receptor family, secretin receptor (secretin), smoothened, Frizzled class receptors (smoothened), trace amine-related receptor family, tachykinin family, thromboxane A2 receptor (TP), thyrotropin-releasing hormone receptor (TRH1), thyrotropin-stimulating hormone receptor (TSH). Examples of protein kinases include, but are not limited to, AP2-related kinase, human ABL proto-oncogene 1 non-receptor tyrosine protein kinase family, c-abl oncogene 1 receptor tyrosine kinase family, v-abl Abelson murine leukemia viral oncogene homolog 2, activin A receptor family, bc1 complex homolog chaperone-ABC1 activity (S. pombe) (ADCK3), aarF domain-containing kinase 4 (ADCK4), v-akt murine thymoma viral oncogene homolog family, anaplastic lymphoma receptor tyrosine kinase family, protein kinase A family, protein kinase B family, ankyrin repeat and kinase domain containing 1 (ANKK1) NUAK family-SNF1-like kinase, mitogen-activated protein kinase kinase kinase family aurora kinase Aurora kinase A (AURKA), Aurora kinase B (AURKB), Aurora kinase C (AURKC), AXL receptor tyrosine kinase (AXL), BMP2-inducible kinase (BIKE), B-lymphocyte tyrosine kinase (BLK), bone morphogenetic protein receptor family, BMX nonreceptor tyrosine kinase (BMX), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), protein tyrosine kinase 6 (BRK), BR serine / threonine kinase family, Bruton's agammaglobulinemia tyrosine kinase (BTK), calcium / calmodulin-dependent protein kinase family, cyclin-dependent kinase family, cyclin-dependent kinase-like family, CHK1 checkpoint homolog (S. pombe) (CHEK1), CHK2 checkpoint homolog (S. pombe) (CHEK2),Insulin receptor isoform A (INSR), insulin receptor isoform B (INSR), rho-interacting serine / threonine kinase (CIT), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), CDC-like kinase family hepatocyte growth factor receptor (MET), proto-oncogene tyrosine-protein kinase receptor, colony-stimulating factor family receptor, c-src tyrosine kinase (CSK), casein kinase family, megakaryocyte-associated tyrosine kinase (CTK), death-associated protein kinase family, doublecortin-like kinase family, discoidin domain receptor tyrosine kinase, myotonic dystrophy protein kinase (DMPK), dual specificity tyrosine-(Y)-phosphorylation-regulated kinase family, epidermal growth factor receptor family, eukaryotic translation initiation factor 2-α kinase 1 (EIF2AK1), EPH receptor family, ephrin type A receptor family, ephrin type B receptor family, v-erb-b2 erythroblastic leukemia viral oncogene homolog family, mitogen-activated protein kinase family Lee, endoplasmic reticulum-nuclear signaling 1 (ERN1), PTK2 protein tyrosine kinase 2 (FAK), fer (fps / fes-related) tyrosine kinase (FER), feline sarcoma oncogene (FES), fibroblast growth factor receptor family, Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog (FGR), fms-related tyrosine kinase family, Fms-related tyrosine kinase family, fyn-related kinase (FRK), SRC-related FYN oncogene, cyclin G-related kinase (GAK), eukaryotic translation initiation factor 2 alpha kinase, growth hormone receptor, G protein-coupled receptor kinase 1 (GRK1), G protein-coupled receptor kinase family, glycogen synthase kinase family, germ cell-associated 2 (haspin) (HASPIN), hematopoietic cell kinase (HCK), homeodomain-interacting protein kinase family, mitogen-activated protein kinase kinase kinase kinase family, hormone signaling-regulated Neu-related kinase (HUNK), enterocyte (MAK-like) kinase (ICK), insulin-like growth factor 1 receptor (IGF1R),conserved helix-loop-helix ubiquitous kinase (IKK-α), inhibitor of kappa light polypeptide gene transcription factor of B-cell kinase β family, insulin receptor (INSR), insulin receptor-related receptor (INSRR), interleukin-1 receptor-related kinase family, IL2-inducible T-cell kinase (ITK), Janus kinase family, kinase insert domain receptor, v, -Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, lymphocyte-specific protein tyrosine kinase (LCK), LIM domain kinase family, serine / threonine kinase family, leucine-rich repeat kinase family, v-yes-1 Yamaguchi sarcoma viral oncogene homolog (LYN), male germline-associated kinase (MAK), MAP / microtubule affinity-regulating kinase family, microtubule-associated serine / threonine kinase family, maternal embryonic leucine zipper kinase, c-mer proto-oncogene tyrosine kinase melanoma kinase (MERTK), met proto-oncogene (hepatocyte growth factor receptor), MAP kinase interacting serine / threonine kinase family, myosin light chain kinase family, mixed lineage kinase domain-like protein isoform, CDC42-binding protein kinase family, serine / threonine kinase family, macrophage-stimulating 1 receptor (c-met-related tyrosine kinase) (MST1R), mechanical target of rapamycin (serine / threonine kinase) (MTOR), musculo-skeletal receptor tyrosine kinase (MUSK), myosin light chain kinase family family, NIMA (not in mitosis gene a)-related kinase family, serine / threonine-protein kinase NIM1 (NIM1), nemo-like kinase (NLK), oxidative stress responsive 1 (OSR1), p21 protein (Cdc42 / Rac)-activated kinase family, PAS domain-containing serine / threonine kinase, platelet-derived growth factor receptor family, 3-phosphoinositide-dependent protein kinase-1 (PDPK1), calcium-dependent protein kinase 1, phosphorylase kinase gamma family, phosphatidylinositol 4,5-bisphosphate 3 kinase, phosphoinositide-3 kinase family, phosphatidylinositol 4 kinase family, phosphoinositide kinase, FYVE finger-containing, Pim-1 oncogene (PIM1), pim-2 oncogene (PIM2), pim-3 oncogene (PIM3), phosphatidylinositol-4-phosphate 5 kinase family, phosphatidylinositol-5-phosphate 4 kinase family protein kinase, membrane-associated tyrosine / threonine 1 (PKMYT1), protein kinase N family,Polo-like kinase family, protein kinase C family, protein kinase D family, cGMP-dependent protein kinase family, eukaryotic translation initiation factor 2-alpha kinase 2 (PRKR), X-linked protein kinase (PRKX), prolactin receptor (PRLR), PRP4·pre-mRNA processing factor 4 homolog B (yeast) (PRP4), PTK2B protein tyrosine kinase 2beta (PTK2B), SIK family kinase 3 (QSK), v-raf-1 murine leukemia viral oncogene homolog 1 (RAF1), neurotrophic tyrosine kinase ze receptor type family, receptor (TNFRSF) interacting serine-threonine kinase family, dual serine / threonine and tyrosine protein kinase (RIPK5), Rho-related coiled-coil-containing protein kinase family, c-ros oncogene 1 receptor tyrosine kinase (ROS1), ribosomal protein S6 kinase family, SH3-binding domain kinase 1 (SBK1), serum / glucocorticoid-regulated kinase family, uncharacterized putative serine / threonine protein kinase (Sugen kinase 110) (SgK11) 0), salt-inducible kinase family, SNF-related kinase (SNRK), src-related kinase, SFRS protein kinase family, spleen tyrosine kinase (SYK), TAO kinase family, TANK-binding kinase 1 (TBK1), tec protein tyrosine kinase (TEC), testis-specific kinase 1 (TESK1), transforming growth factor, beta receptor family, tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE1), TEK tyrosine kinase, endothelial (TIE2), angiopoietin-1 receptor (Tie2), t ousled-like kinase family, TRAF2 and NCK interacting kinase (TNIK), non-receptor tyrosine kinase family, TNNI3 interacting kinase (TNNI3K), transient receptor potential cation channel, testis-specific serine kinase family, TTK protein kinase (TTK), TXK tyrosine kinase (TXK), tyrosine kinase 2 (TYK2), TYRO3 protein tyrosine kinase (TYRO3), unc-51-like kinase family, phosphatidylinositol 3-kinase, vaccinia-related kinase 2 (VRK2),WEE1 homolog family, WNK lysine-deficient protein kinase family, v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 (YES), bactericidal alpha motif and leucine zipper-containing kinase AZK (ZAK), zeta chain (TCR)-associated protein kinase 70 kDa (ZAP70). Nuclear hormone receptors include, but are not limited to: Androgen receptor (AR), estrogen-related receptor α (ESRRA), estrogen receptor 1 (ESR1), nuclear receptor subfamily 1 group H member 4 (NR1H4), nuclear receptor subfamily 3 group C member 1 (glucocorticoid receptor) (NR3C1), nuclear receptor subfamily 1 group H member 3 (liver X receptor α) (NR1H3), nuclear receptor subfamily 1 group H member 2 (liver X receptor β) (NR1H2), nuclear receptor subfamily 1 group H member 2 (liver X receptor β) (NR1H2), nuclear receptor subfamily 3 group C member 2 (electrocorticoid receptor) (NR3C2), peroxisome proliferator-activated receptor α (PPARA), peroxisome proliferator-activated receptor α (PPARA), Peroxisome proliferator-activated receptor gamma (PPARG), peroxisome proliferator-activated receptor delta (PPARD), progesterone receptor alpha (PGR), progesterone receptor beta (PGR), retinoic acid receptor alpha (RARA), retinoic acid receptor-beta (RARB), retinoid X receptor alpha (RXRA), retinoid X receptor gamma (RXRG), thyroid hormone receptor alpha (THRA), thyroid hormone receptor beta (THRB), retinoic acid-related orphan receptor, liver X receptor, farnesoid X receptor, vitamin D receptor, pregnane X receptor, constitutive androstane receptor, hepatocyte nuclear factor 4, estrogen receptor, estrogen-related receptor, glucocorticoid receptor, nerve growth factor-inducible gene B, germ cell nuclear factor. Epigenetic targets include, but are not limited to, the following: ATPase family AAA domain-containing protein 2 (ATAD2A), ATPase family AAA domain-containing 2B (ATAD2B), ATPase family AAA domain-containing 2B (ATAD2B), zinc finger domain 1A adjacent bromodomain (BAZ1A),Zinc finger domain 1B adjacent bromodomain (BAZ1B), zinc finger domain 2A bromodomain (BAZ2A), zinc finger domain 2A adjacent bromodomain (BAZ2A), zinc finger domain 2B adjacent bromodomain (BAZ2B), bromodomain-containing protein 1 (BRD1), bromodomain-containing protein 2 first bromodomain (BRD2), bromodomain-containing protein 2 first and second bromodomains (BRD2), bromodomain-containing protein 2 isoform 1 bromodomain 2 (BR D2(2)), bromodomain-containing protein 3 bromodomain 1 (BRD3(1)), bromodomain-containing protein 3 first bromodomain (BRD3), bromodomain-containing protein 3 first and second bromodomains (BRD3), bromodomain-containing protein 3 bromodomain 2 (BRD3(2)), bromodomain-containing protein 4 first bromodomain (BRD4), bromodomain-containing protein 4 isoform long bromodomains 1 and 2 (BRD4(1-2)), bromodomain-containing protein 4 isoform long ng-type bromodomain 2 (BRD4(2)), bromodomain-containing protein 4 isoform short (BRD4(full-length-short isoform)), bromodomain-containing protein 7 (BRD7), bromodomain-containing 8 bromodomain 1 (BRD8(1)), bromodomain-containing 8 bromodomain 2 (BRD8(2)), bromodomain-containing protein 9 isoform 1 (BRD9), bromodomain-containing testis-specific first bromodomain (BRDT), bromodomain-containing testis-specific first and second bromodomains (BRDT ), bromodomain testis specific protein isoform b bromodomain 2 (BRDT(2)), bromodomain and PHD finger containing 1 (BRPF1), bromodomain and PHD finger containing 3 (BRPF3), bromodomain and PHD finger containing 3 (BRPF3), bromodomain and WD repeat containing 3 second bromodomain (BRWD3(2)), cat eye syndrome critical region protein 2 (CECR2), CREB binding protein (CREBBP), E1A binding protein p300 (EP300), EP300 (EP300),Nucleosome remodeling factor subunit BPTF isoform 1 (FALZ), nucleosome remodeling factor subunit BPT (FALZ), euchromatin histone lysine N-methyltransferase 2 (EHMT2), histone acetyltransferase KAT2A (GCN5L2), euchromatin histone lysine N-methyltransferase 1 (EHMT1), histone lysine N-methyltransferase MLL (MLL), polybromo 1 first bromodomain (PB1(1)), polybromo 1 second bromodomain (PB1(1)), domain (PB1(2)), polybromo 1 bromodomain 2 (PBRM1(2)), polybromo 1 bromodomain 5 (PBRM1(5)), histone acetyltransferase KAT2B (PCAF), PH interacting protein first bromodomain (PHIP(1)), PH interacting protein second bromodomain (PHIP(2)), protein kinase C binding protein 1 (PRKCBP1), protein arginine N-methyltransferase 3 (PRMT3), SWI / S of chromatin subfamily a member 2 SWI / SNF-related matrix-associated actin-dependent regulator of chromatin subfamily a member 4 (SMARCA4), nuclear structural protein SP110 (SP110), nuclear structural protein SP140 (SP140), transcription initiation factor TFIID subunit 1 (TAF1(1-2)), TAF1·RNA polymerase II-TATA box-binding protein (TBP)-associated factor-250 kDa-bromodomain 2 (TAF1(2)), transcription initiation factor TFIID subunit 1-like first bromodomain (TAF1L(1)), transcription initiation factor TFIID subunit 1-like second bromodomain (TAF1L(2)), tripartite motif-containing 24 (TRIM24(bromo)), tripartite motif-containing 24 (TRIM24(PHD-bromo)), E3 ubiquitin protein ligase TRIM33 (TRIM33), tripartite motif-containing 33 (TRIM33(PHD-bromo)), WD repeat 9 first bromodomain (WDR9(1)), WD repeat 9 second bromodomain (WDR9(2)). Membrane transport proteins include, but are not limited to,These include: ATP-binding cassette (ABC) superfamily, solute carrier (SLC) superfamily, multidrug resistance protein 1 (P-glycoprotein), organic anion transporter 1, and proteins such as EAAT3, EAAC1, EAAT1, GLUT1, GLUT2, GLUT9, GLUT10, rBAT, AE1, NBC1, KNBC, CHED2, BTR1, NABC1, CDPD, SGLT1, SGLT2, NIS, CHT1, NET, DAT, GLYT2, CRTR, B0AT1, SIT1, XT3, y+LAT1, BAT1, NHERF1, NHE6, ASBT, DMT1, DCT1, NRAMP2, NKCC2, NCC, KCC3, NACT, MCT1, MCT8, MCT12, SLD, VGLUT 3, THTR1, THTR2, PIT2, GLVR2, OCTN2, URAT1, NCKX1, NCKX5, CIC, PiC, ANT1, ORNT1, AGC1, ARALAR, Citrin, STLN2, aralar2, TPC, MUP1, MCPHA, CACT, GC1, P HC, DTD, CLD, DRA, PDS, Prestin, TAT1, FATP4, ENT3, ZnT2, ZnT10, AT1, NPT2A, NPT2B, HHRH, CST, CDG2F, UGAT, UGTL, UGALT, UGT1, UGT2, FUCT1, CDG2C, NST, PAT2, G6PT1, SPX4, ZIP4, LIV4, ZIP13, LZT-Hs9, FPN1, MTP1, IREG1, RHAG, AIM1, PCFT, FLVCR1, FLVCR2, RFT1, RFT2, RFT3, OATP1B1, OATP1B3, OATP2A1. Structural proteins include, but are not limited to, heat shock proteins, microtubule stabilizing proteins, oncoprotein 18, stathmin, kinesin 8 and kinesin 14 family, Kip3, Kif18A. Proteases include, but are not limited to, the ADAM (a disintegrin and metalloprotease) family.Other molecular targets of signal transduction include, but are not limited to, cell division cycle gene 25 homolog A (CDC25A), forkhead box protein O3 (forkhead box protein O3), nuclear factor of B-cell inhibitory factor kappa light polypeptide gene transcription factor, alpha (NFKBIA), nuclear factor (erythroid-derived 2)-like 2 (NFE2L2), natriuretic peptide receptor A (NPR1), tumor necrosis factor receptor superfamily, member 11a (TNFRSF11A), v-rel reticuloendotheliosis viral oncogene homolog A (avian) (RELA), sterol regulatory element-binding transcription factor 2 (SREBF2), CREB-regulated transcriptional coactivator 1 (CRTC1), CREB-regulated transcriptional coactivator 2 (CRTC2), X-box binding protein 1 (XBP1), catenin (cadherin-associated protein), beta 1 (CTNNB1), and combinations thereof.
[0096] Well-known biologics include, but are not limited to, the following: Abbosynagis, Abegrin, Actemra, tacatuzumab (AFP-Cide), Antova, Arzerra, Aurexis, Avastin, Benlysta, Bexxar, Blontress, Mepolizumab (Bosat ria), alemtuzumab (Campath), labetuzumab (CEA-Cide), CEA-Scan, Cimzia, Cyramza, Ektomab, cetuximab (Erbitux), biciromab (FibriScint), obinutuzumab (Gazyva), Herceptin, clivatuzumab tetraxetan (hPAM4-Cide), votumumab (HumaSPECT), zanolimumab (HuMax-CD4), zalutumumab (HuMax-EGFr), adalimumab (Humira), fontolizumab (HuZAF), altumomab pentetate (Hybri-ceaker), canakinumab (Ilaris), igovomab (Indimacis-125), Kadcyla, alemtuzumab (Lemtrada), LeukArrest, suresomab (LeukoScan), ranibizumab (Lucentis), Lymphomun, Lymphoscan (Lymp hoScan), belimumab (LymphoStat-B), rituximab (MabThera), efungumab (Mycograb), gemtuzumab ozogamicin (Mylotarg), imciromab (Myoscint), technetium fanolesomab (NeutroSpec), motavizumab (Numax), Nuvion, pertuzumab (Omnitarg), Opdivo, muromonab-CD3 (Orthoclone OKT3), OvaRex, Panorex, denosumab (Prolia), capromab pendetide (Prostascint), efalizumab (Raptiva),Infliximab (Remicade), catumaxomab (Removab), Rencarex, abciximab (ReoPro), ertumaxomab (Rexomun), rituximab (Rituxan), tocilizumab (RoActemra), 99mTc-besilesomab (Scintimun), golimumab (Simponi), basiliximab (Simulect), eculizumab (Soliris), ustekinumab (Stelara), palivizumab (Synagis), Tactress, nimotuzumab (Theracim), pemtumomab (Theragyn), nimotuzumab (Theraloc), natalizumab (Tysabri), panitumumab (Vectibix), nofetumomab (Verluma), omalizumab (Xolair), ipilimumab (Yervoy), daclizumab (Zenapax), and ibritumomab tiuxetan (Zevalin), or combinations.
[0097] Well-known monoclonal antibodies include, but are not limited to, 3F8, 8H9, abagovomab, abciximab, avituzumab, abrilumab, actoxumab, adalimumab, adecatumumab, aducanumab, afacevicumab, afelimomab, afutuzumab, alacizumab pegol, ALD518, ALD403, alemtuzumab, alirocumab, altumomab pentetate, amatuximab, AMG334, anatumomab mafenatox, anetumab ravtansine, aniformumab, anrukinzumab, apolizumab, arcitumomab, asclinbacumab, acelizumab, and atezolizumab. Mab, atinumab, atlizumab, atolimumab, avelumab, bapineuzumab, basiliximab, bavituximab, bectumomab, begelomab, belimumab, benralizumab, bertilimumab, besilesomab, bevacizumab, bezlotoxumab, biciromab, bimagrumab, bimekizumab, bivatuzumab mertansine, bleselumab, blinatumomab, brontuzumab, brosozumab, bococizumab, brazikumab, brentuximab vedotin, briakinumab, brodalumab, brolucizumab, brontiximab, bro Sumab, cabilalizumab, canakinumab, cantuzumab mertansine, cantuzumab lavtansine, caplacizumab, capromab pendetide, carlumab, carotuximab, catumaxomab, cBR96-doxorubicin immunoconjugate, cedelizumab, sergituzumab amnaleukin, certolizumab pegol, cetuximab, sitatuzumab bogatox, cixutumumab, clazakizumab, clenoliximab, clivatuzumab tetraxetan, codrituzumab, cortuximab lavtansine, conatumumab, concizumab, CR626 1. Crenezumab, Clotedumab, Dacetuzumab, Daclizumab, Darotuzumab, Dapirorizumab pegol, Daratumumab, Dectrekumab, Demcizumab, Denintuzumab mafodotin, Denosumab, Depatuxizumab mafodotin, Delrotuximab biotin, Detumomab, Dinutuximab, Ziridabumab, Domaglozumab, Dorlimomab aritox, Drozitumab, Durigotumab, Dupilumab, Durvalumab, Dusigitumab, Eclomeximab, Eculizumab, Edobacomab, Edrecolomab,Efalizumab, Efangumab, Eldelumab, Elgemtuzumab, Elotuzumab, Ercilimomab, Emactuzumab, Emivetuzumab, Emicizumab, Enavatuzumab, Enfortumab vedotin, Enlimomab pegol, Enoblituzumab, Enokizumab, Enoticumab, Ensituximab, Epitumomab cituxetan, Epratuzumab, Erenumab, Erlizumab, Ertumaxomab, Etaracizumab, Etrolizumab, Ebinacumab, Evolocumab, Exibirumab, Fanolesomab, Faralimomab, Faretuzumab, Fasinumab, FBTA0 5, Felvizumab, Fezakinumab, Fivatuzumab, Ficlatuzumab, Figitumumab, Filibumab, Framvotumab, Fretikumab, Fontolizumab, Foralumab, Foravirumab, Fresolimumab, Furlanumab, Futuximab, Galcanezumab, Galiximab, Ganitumab, Gantenerumab, Gavilimomab, Gemtuzumab ozogamicin, Gevokizumab, Girentuximab, Glenbatumumab vedotin, Golimumab, Gomiliximab, Guselkumab, Ibalizumab, Ibritumomab tiuxetan, Icrucumab, Idarucizumab, Igobo Mab, IMA-638, IMAB362, Imalumab, Imicilomab, Imgatuzumab, Inclacumab, Indatuximab vedotin, Inebilizumab, Infliximab, Inolimomab, Inotuzumab ozogamicin, Intetumumab, Ipilimumab, Iratumumab, Isatuximab, Itolizumab, Ixekizumab, Keliximab, Labetuzumab, Lambrolizumab, Lampalizumab, Lanadelumab, Landgrotumab, Laprituximab emtansine, LBR-101 / PF0442g7429, Lebrikizumab, Lebrikizumab Maresomab, Lendalizumab, Lenzilumab, Lerdelimumab, Lexatumumab, Ribivirumab, Rifastuzumab vedotin, Ligelizumab, Rilotumab satetraxetan, Lintuzumab, Lirilumab, Roderucizumab, Loxivetumab, Lorvotuzumab mertansine, Lukatumumab, Lulizumab pegol, Lumiliximab, Lumuletuzumab, LY2951742, Mapatumumab, Marjetuximab, Maslimomab, Matuzumab, Mavrilimumab, Mepolizumab, Metelimumab, Milatuzumab, Minretumomab, Mirvetuximab soravtansine, Mitumomab,Mogamulizumab, monalizumab, morolimumab, motavizumab, moxetumomab pseudotox, muromonab-CD3, nacolomab butafenatox, namilumab, naptumomab estafenatox, naratuximab emtansine, narutumab, natalizumab, nabicixizumab, nabivumab, nebacumab, necitumumab, nemolizumab, nerelimomab, nesbacumab, nimotuzumab, nivolumab, nofetumomab merpentane, obiltoxaximab, obinutuzumab, ocralizumab, ocrelizumab, odulimomab, ofatumumab, olaratumumab , olokizumab, omalizumab, onartuzumab, ontuxizumab, opicinumab, oportuzumab monatox, oregovomab, olticumab, otelixizumab, otlertuzumab, oxelumab, ozonazumab, pasivaximab, palivizumab, pamrevlumab, panitumumab, pancomab, panobacumab, palsatuzumab, pascolizumab, pasotuxizumab, pateclizumab, patritumab, pembrolizumab, pemtumomab, perakizumab, pertuzumab, pexelizumab, pidilizumab, pinatuzumab vedotin, pintum Mab, placulumab, prozalizumab, pogalizumab, polatuzumab vedotin, ponezumab, prezalizumab, priliximab, pritoxaximab, pritumumab, PRO140, kirisumab, racotumomab, radletumab, rafivirumab, ralpancizumab, ramucirumab, ranibizumab, raxibacumab, refanezumab, regavirumab, reslizumab, rilotumumab, rinukumab, risankizumab, rituximab, rivavazumab pegol, lobatumumab, loredumab, romosozumab, rontalizumab, rovalpituzumab tesirin, rovelizumab, Ruplizumab, sacituzumab govitecan, samalizumab, sapelizumab, sarilumab, satumomab pendetide, secukinumab, seribantumab, setoxaximab, sevilumab, SGN-CD19A, SGN-CD33A, sibrotuzumab, sifalimumab, siltuximab, simtuzumab, siplizumab, sirukumab, sofituzumab vedotin, solanezumab, solitomab, sonepcizumab, sontuzumab, stamulumab, sulesomab, subizumab, tabalumab, tacatuzumab tetraxetan, tadocizumab, talizumab, tamtubetumab, tanezumab,Taplitumomab paptox, talextumab, tefibazumab, terimomab alitox, tenatumomab, teneliximab, teplizumab, teprotumumab, tesidolumab, tetulomab, tezepelumab, TGN1412, ticilimumab, tigatuzumab, tildrakizumab, timolumab, tisotumab vedotin, TNX-650, tocilizumab, toralizumab, tosatoxumab, tositumomab, tobetumab, tralokinumab, trastuzumab, trastuzumab emtansine, TRBS07, tregalizumab, tremelimumab, trevoglumab, tucotuzumab selmo Leukine, tubilumab, ublituximab, urocupulumab, urelumab, urtoxazumab, ustekinumab, utomilumab, vadastuximab butarilin, bundletuzumab vedotin, vanticutumab, vanucizumab, bapaliximab, varlilumab, batelizumab, vedolizumab, veltuzumab, beparimomab, besencumab, visilizumab, bovalilizumab, volociximab, borsetuzumab mafodotin, votumumab, xentuzumab, zalutumumab, zanolimumab, zatuximab, diralimumab, and zolimomab alitox, or combinations thereof.
[0098] Vaccines developed for viral diseases include, but are not limited to, hepatitis A vaccine, hepatitis B vaccine, hepatitis E vaccine, HPV vaccine, influenza vaccine, Japanese encephalitis vaccine, MMR vaccine, MMRV vaccine, polio vaccine, rabies vaccine, rotavirus vaccine, chickenpox vaccine, shingles vaccine, smallpox vaccine, yellow fever vaccine, adenovirus vaccine, coxsackievirus B vaccine, cytomegalovirus vaccine, human dengue vaccine, human eastern equine encephalitis virus vaccine, Ebola vaccine, enterovirus 71 vaccine, Epstein-Barr vaccine, hepatitis C vaccine, HIV vaccine, human HTLV-1 T-lymphotropic leukemia vaccine, Marburg virus disease vaccine, norovirus vaccine, human respiratory syncytial virus vaccine, severe acute respiratory syndrome (SARS) vaccine, and human West Nile virus vaccine. Vaccines developed for bacterial diseases include, but are not limited to, anthrax vaccine, DPT vaccine, Q fever vaccine, Hib vaccine, tuberculosis (BCG) vaccine, meningococcal vaccine, typhoid vaccine, pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine, cholera vaccine, dental caries vaccine, ehrlichiosis vaccine, leprosy vaccine, Lyme disease vaccine, Staphylococcus aureus vaccine, Streptococcus pyogenes vaccine, syphilis vaccine, tularemia vaccine, and Yersinia pestis vaccine. Vaccines developed for parasitic diseases include, but are not limited to, malaria vaccine, schistosomiasis vaccine, Chagas disease vaccine, hookworm vaccine, human onchocerciasis river blindness, trypanosomiasis vaccine, and visceral leishmaniasis vaccine. Non-communicable diseases include, but are not limited to, Alzheimer's disease amyloid protein vaccine, breast cancer vaccine, ovarian cancer vaccine, prostate cancer vaccine, and talimogene laherparepvec (T-VEC).Vaccines also include, but are not limited to, the following trade names: ACAM2000, ActHIB, Adacel, Afluria, AFLURIA QUADRIVALENT, Agriflu, BCG Vaccine, BEXSERO, Biothrax, Boostrix, Cervarix, Comvax, DAPTACEL, DECAVAC, Engerix-B, FLUAD, Fluarix, Fluarix Quadrivalent, Flublok, Flucelvax, Flucelvax Quadrivalent, FluLaval, FluMist, FluMist Quadrivalent, Fluvirin, Fluzone Quadrivalent, Fluzone, Fluzone High-Dose and Fluzone Intradermal, Gardasil, and Gardasil. 9, Havrix, Hiberix, Imovax, Infanrix, IPOL, Ixiaro, JE-Vax, KINRIX, Menactra, MenHibrix, Menomune-A / C / Y / W-135, Menveo, MMR II, MM-Vax, Pediarix, PedvaxHIB, Pentacel, Pneumovax 23, Poliovax, Prevnar, Prevnar 13, ProQuad, Quadracel, Quadrivalent, RabAvert, Recombivax HB, ROTARIX, RotaTeq, TENIVAC, TICE BCG, Tripedia, TRUMENBA, Twinrix, TYPHIM Vi, VAQTA, Varivax, Vaxchora, Vivotif, YF-Vax, Zostavax, and combinations thereof.
[0099] Injectable drugs include, but are not limited to, the following: Ablavar (Gadofosveset Trisodium Injection), Abarelix Depot, Botulinum Toxin A Injection (Dysport), ABT-263, ABT-869, ABX-EFG, Accretropin (Somatropin Injection), Acetadote (Acetylcysteine Injection), Acetazolamide Injection, Acetylcysteine Injection (Acetadote), Actemra (Tocilizumab Injection), Acthrel (Corticolerin Aubain Triflutate for Injection), Actummune, Activase, Acyclovir for Injection (Zovirax Injection), Adacel, Adalimumab, Adenoscan (Adenosine Injection), Adenosine Injection (Adenosine Injection), can), Adrenaclick, AdreView (iobenguane 1123 injection, for intravenous administration), Afluria, Ak-Fluor (fluorescein injection), Aldurazyme (laronidase), alglucerase injection (Ceredase), Alkeran injection (melphalan Hcl injection), allopurinol sodium for injection (Aloprim), Aloprim (allopurinol sodium for injection), alprostadil, Alsuma (sumatriptan injection), ALTU-238, amino acid injection, Aminosyn, Apidra, Apremilast, alprostadil dual chamber injection (Caverject Impulse), AMG009, AMG076, AMG102, AMG108, AMG114, AMG162, AMG220, AMG221, AMG222, AMG223, AMG317, AMG379, AMG386, AMG403, AMG477, AMG479, AMG517, AMG531, AMG557, AMG623, AMG655, AMG706, AMG714, AMG745, AMG785, AMG811, AMG827, AMG837, AMG853, AMG951, Amiodarone HCl Injection, Amobarbital Sodium Injection, Amytal SodiumSodium (amobarbital sodium injection), Anakinra, Anti-Abeta, Anti-Beta7, Anti-Beta20, Anti-CD4, Anti-CD20, Anti-CD40, Anti-IFNα, Anti-IL13, Anti-OX40L, Anti-oxLDS, Anti-NGF, Anti-NRP1, Arixtra, Amphadase (hyaluronidase injection), Ammonul (sodium phenylacetate and sodium benzoate injection), Anaprox, Anzemet injection (dolasetron mesylate injection), Apidra (insulin glulisine [rDNA derived] injection), Apomab, Aranesp (darbepoetin α), Argatroban (argatroban injection), Arginine hydrochloride injection (R-Gene 10, Aristocort, Aristospan, Arsenic Acid Injection (Trisenox), Articane HCl and Epinephrine Injection (Septocaine), Arzerra (Ofatumumab Injection), Asclera (Polidocanol Injection), Ataluren, Ataluren-DMD, Atenolol Injection (Tenormin Intravenous Injection), Atracurium Besylate Injection, Avastin, Azactam Injection, Azithromycin (Zithromax Injection), Aztreonam Injection, Baclofen Injection (Lioresal Intrathecal), Bacteriostatic Water (Bacteriostatic Water, for Injection), Baclofen Injection (Lioresal Intrathecal), Bal in Oil Ampules (dimercarprol injection), BayHepB, BayTet, Benadryl, bendamustine hydrochloride injection (Treanda), benztropine mesylate injection (Cogentin), betamethasone injectable suspension (Celestone Soluspan), Bexxar, Bicillin CR900 / 300 (Penicillin G Benzathine and Penicillin G Procaine Injection), Blenoxane (Bleomycin Sulfate Injection), Bleomycin Sulfate Injection (Blenoxane), Boniva Injection (Ibandronate Sodium Injection), Botox Cosmetic (OnabotulinumtoxinA, for injection), BR3-FC, Bravelle (Urofollitropin Injection), Bretylium (Bretylium Tosylate Injection), Brevital Sodium (Methohexital Sodium, for injection), Brethine, Briobacept, BTT-1023, Bupivacaine HCl, Byetta, Ca-DTPA (Calcium Pentetate Trisodium Injection), Cabazitaxel Injection (Jevtana), Caffeine Alkaloid (Caffeine and Sodium Benzoate Injection), Calcijex Injection (Calcitriol), Calcitriol (Calcijex Injection), Calcium Chloride (Calcium Chloride Injection 10%), Calcium Disodium Versenate (Calcium Disodium Edetate Injection), Campath (Artemtuzumab), Camptosar Injection (Irinotecan Hydrochloride), Canakinumab Injection (Ilaris), Capastat Sulfate (Capreomycin, for Injection), Capreomycin for Injection (Capastat Sulfate), Cardiolite (Technetium Tc99 Sestamibi Prep Kit for Injection), Carticel, Cathflo, Cefazolin, Dextrose for Injection (Cefazolin Injection), Cefepime Hydrochloride chloride, Cefotaxime, Ceftriaxone, Cerezyme, Carnitor Injection, Caverject, Celestone Soluspan, Celsior, Cerebyx (Fosphenytoin Sodium Injection), Ceredase (Alglucerase Injection), Ceretec (Technetium Tc99m Examethazime Injection), Certolizumab, CF-101, Chloramphenicol Sodium Succinate (Chloramphenicol Sodium Succinate Injection), Chloramphenicol Sodium Succinate InjectionSuccinate), Cholestagel (Colesevelam Hydrochloride), Choriogonadotropin Alpha Injection (Ovidrel), Cimzia, Cisplatin (Cisplatin Injection), Clolar (Clofarabine Injection), Clomiphine Citrate, Clonidine Injection (Duraclon), Cogentin (Benzotropine Mesylate Injection), Colitimethate Injection (Coly-Mycin M), Coly-Mycin M (Colistimethate Injection), Compath, Conivaptan Hydrochloride Injection (Vaprisol), Conjugated Estrogens for Injection (Premarin Injection), Copaxone, Corticorelin Oubain Triflutate for Injection (Acthrel), Corvert (Ibutilide Fumarate Injection), Cubicin (Daptomycin Injection), CF-101, Cyanokit (Hydroxocobalamin for Injection), Cytarabine Liposomal Injection (DepoCyt), Cyanocobalamin, Cytovene (ganciclovir), DHE 45, Dacetuzumab, Dacogen (Decitabine Injection), Dalteparin, Dantrium IV (Dantrolene Sodium for Injection), Dantrolene Sodium for Injection (Dantrium IV), Daptomycin Injection (Cubicin), Darbepoietin Alfa, DDAVP Injection (Desmopressin Acetate Injection), Decavax, Decitabine Injection (Dacogen), Dehydrated Alcohol (Absolute Alcohol Injection), Denosumab Injection (Prolia), Delatestryl, Delestrogen, Delteparin Sodium, Depacon (Sodium Valproate Injection), Depo Medrol (Methylprednisolone Acetate Injectable Suspension), DepoCyt (Cytarabine Liposomal Injection), DepoDur (Morphine Sulfate XR Liposomal Injection), Desmopressin Acetate Injection (DDAVP Injection), Depo-Estradiol, Depo-Provera 104 mg / ml, Depo-Provera 150 mg / ml, Depo-Testosterone, Dexrazoxane for Injection, Intravenous Injection Only (Totect), Dextrose / Electrolytes, Dextroseand Sodium Chloride Injection (0.9% Sodium Chloride Solution in 5% Dextrose), Dextrose, Diazepam Injection, Digoxin Injection (Lanoxin Injection), Dilaudid-HP (Hydromorphone Hydrochloride Injection), Dimercaprol Injection (Bal in Oil Ampules), Diphenhydramine Injection (Benadryl Injection), Dipyridamole Injection, DMOAD, Docetaxel for Injection (Taxotere), Dolasetron Mesylate Injection (Anzemet Injection), Doribax (Dripenem for Injection), Doripenem for Injection (Doribax), Doxercalciferol Injection (Hectorol Injection), Doxil (Doxorubicin Hydrochloride Liposomal Injection), Doxorubicin Hydrochloride Liposomal Injection (Doxil), Duraclon (Clonidine Injection), Duramorph (Morphine Injection), Dysport (Abobotulinum Toxin A Injection), Ecallantide Injection (Kalbitor), EC-Naprosyn (Naproxen), Calcium Disodium Edetate Injection (Calcium Disodium Versenate), Edex (Alprostadil Injection), Engerix, Edrophonium Injection (Enlon), Eliglustat Tartate, Eloxatin (Oxaliplatin Injection), Emend Injection (Fosaprepitant Dimeglumine Injection), Enalaprilat Injection, Enlon (Edrophonium Injection), Enoxaparin Sodium Injection (Lovenox), Eovist (Gadoxetate Disodium Injection), Enbrel (Etanercept), Enoxaparin, Epicel, Epinepherine, Epipen, Epipen Jr., Epratuzumab, Erbitux, Ertapenem Injection (Invanz), Erythropoieten, Essential Amino Acid Injection (Nephramine), Estradiol Cypionate, EstradiolValerate, Etanercept, Exenatide Injection (Byetta), Evlotra, Fabrazyme (Adalusidase beta), Famotidine Injection, FDG (Flu deoxyglucose F18 Injection), Feraheme (Ferumoxytol Injection), Feridex IV (Ferumoxides Injectable Solution), Fertinex, Ferumoxides Injectable Solution (Feridex IV), Ferumoxytol Injection (Feraheme), Flagyl Injection (Metronidazole Injection), Fluarix, Fludara (Fludarabine Phosphate), Fludeoxyglucose F18 (FDG), Fluorescein Injection (Ak-Fluor), Follistim AQ Cartridge (Follitropin beta Injection), Follitropin alpha Injection (Gonal-f RF) F), Follitropin beta injection (Follistim AQ Cartridge), Folotyn (pralatrexate solution for intravenous injection), Fondaparinux, Forteo (teriparatide (rDNA derived) injection), Fostamatinib, fosaprepitant dimeglumine injection (Emend injection), foscarnet sodium injection (Foscavir), Foscavir (foscarnet sodium injection), fosphenytoin sodium injection (Cerebyx), fospropofol disodium injection (Lusedra), Fragmin, Fuzeon (enfuvirtide), GA101, Gadobenate dimeglumine injection (Multihance), Gadofosveset trisodium injection (Ablavar), Gadoteridol injection (ProHance), Gadoversetamide injection (OptiMARK), Gadoxetate disodium injection (Eovist), Ganirelix (Ganirelix acetate injection), Gardasil, GC1008, GDFD, Gemtuzumab ozogamicin for injection (Mylotarg), Genotropin, Gentamicin injection, GENZ-112638, Golimumab injection (Simponi injection), Gonal-f RFF (Follitropin alfa injection), Granisetron hydrochloride (Kytril injection), Gentamicin sulfate, Glatiramer acetate, Glucagen, Glucagon, HAE1, Haldol (haloperidol injection), Havrix, Hectorol injection (doxercalciferol injection), Hedgehog signaling pathway inhibitors, Heparin, Herceptin, human granulocyte colony-stimulating factor (hG-CSF), Humalog, human growth hormone, Humatrope, HuMax, Humegon, Humira, Humulin, Ibandronate sodium injection (Boniva injection), Ibuprofen lysine injection (NeoProfen), Ibutilide fumarate injection (Corvert), Idamycin PFS (idarubicin hydrochloride injection), Idarubicin hydrochloride injection (Idamycin PFS), Ilaris (canakinumab injection), injectable imipenem / cilastatin (PrimaxinIV), Imitrex, Incobotulinumtoxin A for Injection (Xeomin), Increlex (Mecasermin [rDNA-derived] Injection), Indocin IV (Indomethacin Injection), Indomethacin Injection (Indocin IV), Infanrix, Innohep, Insulin, Insulin Aspart [rDNA-derived] Injection (NovoLog), Insulin Glargine [rDNA-derived] Injection (Lantus), Insulin Glulisine [rDNA-derived] Injection (Apidra), Interferon alpha-2b, Recombinant for Injection (Intron A), Intron A (Interferon alpha-2b, Recombinant for Injection), Invanz (Ertapenem Injection), Invega Sustenna (Paliperidone Palmitate Extended Release Injectable Suspension), Invirase (Saquinavir Mesylate), Iobenguane 1123 Injection for Intravenous Use (AdreView), Iopromide Injection (Ultravist), Ioversol Injection (Optiray Injection), Iplex (Mecasermin Linfavert [rDNA-derived] Injection), Iprivask, Irinotecan Hydrochloride (Camptosar Injection), Sugar-containing Iron Oxide Injection (Venofer), Istodax (Romidepsin for Injection), Itraconazole Injection (Sporanox Injection), Jevtana (Cabazitaxel Injection), Jonexa, Kalbitor (Ecallantide Injection), KCL in D5NS (Potassium Chloride in Dextrose 5% and Sodium Chloride Injection), KCL in D5W, KCL in NS, Kenalog 10 Injection (Triamcinolone Acetonide Injectable Suspension), Kepivance (Palifermin), Keppra Injection (Levetiracetam), Keratinocyte, KFG, Kinase Inhibitors, Kineret (Anakinra), Kinlytic (Urokinase Injection), Kinrix, Klonopin (Clonazepam), Kytril Injection (Granisetron Hydrochloride), Lacosamide Tablets and Injection (Vimpat), Lactated Ringer's Solution, Lanoxin Injection (Digoxin Injection), Lansoprazole for Injection (Prevacid IV), Lantus, Leucovorin Calcium (Leucovorin Calcium Injection), Lente(L), Leptin, Levemir, Leukine Sargramostim, Leuprolide Acetate, Levothyroxine, Levetiracetam (Keppra Injection), Lovenox, Levocarnitine Injection (Carnitor Injection), Lexiscan (Regadenoson Injection), Lioresal Intrathecal (Baclofen Injection), Liraglutide [rDNA] Injection (Victoza), Lovenox (Enoxaparin Sodium Injection), Lucentis (Ranibizumab Injection), Lumizyme, Lupron (Leuprolide Acetate Injection), Lusedra (Fospropofol Disodium Injection), Maci, Magnesium Sulfate (Magnesium Sulfate Injection), Mannitol Injection (Mannitol IV), Marcaine (Bupivacaine Hydrochloride and Epinephrine Injection), Maxipime (Cefepime Hydrochloride for Injection), MDP Multidose Kit of Technetium Injection (Technetium Tc99m Medronate Injection), Mecasermin [rDNA-derived] Injection (Increlex), Mecasermin Linfavert [rDNA-derived] Injection (Iplex), Melphalan Hydrochloride Injection (Alkeran Injection), Methotrexate, Menactra, Menopur (Menotropins Injection), Menotropins for Injection (Repronex), Methohexital Sodium for Injection (Brevital Sodium), Methyldoparin Hydrochloride Injection, Solution (Methyldoparin Hydrochloride), Methylene Blue (Methylene Blue Injection), Methylprednisolone Acetate Injectable Suspension (DepoMedrol), MetMab, Metoclopramide Injection (Reglan Injection), Metrodin (Urofollitropin for Injection), Metronidazole Injection (Flagyl Injection), Miacalcin, Midazolam (Midazolam Injection), Mimpara (Cinacalcet), Minocin Injection (Minocycline Injection), Minocycline Injection (Minocin Injection), Mipomersen, Mitoxantrone for Injection Concentrate (Novantrone), Morphine Injection (Duramorph), Morphine Sulfate XR Liposomal Injection (DepoDur), Morrhuate Sodium (Sodium Morrhuate Injection), Motesanib, Mozobil (Plerixafor Injection), Multihance (Gadobenate Dimeglumine Injection), Combined Electrolytes and Dextrose Injection, Combined Electrolytes Injection, Mylotarg (Gemtuzumab Ozogamicin for Injection), Myozyme (Alglucosidase Alfa), Nafcillin Injection (Nafcillin Sodium), Nafcillin Sodium (Nafcillin Injection), Naltrexone XR Injection (Vivitrol), Naprosyn (Naproxen), NeoProfen (Ibuprofen Lysine Injection), Nandrol Decanoate, Neostigmine Methylsulfate (Neostigmine Methylsulfate Injection), NEO-GAA, NeoTect (Technetium Tc99m Depreotide Injection), Nephramine (Essential Amino Acid Injection), Neulasta (Pegfilgrastim), Neupogen (Filgrastim), Novolin, Novolog, NeoRecormon, Neutrexin (Trimetrexate Glucuronate Injection), NPH(N), Nexterone (Amiodarone Hydrochloride Injection), Norditropin (Somatropin Injection), Normal Saline (Sodium Chloride Injection), Novantrone (Mitoxantrone for Injection Concentrate), Novolin 70 / 30 Innolet (70%NPH, Human Isophane Insulin Suspension and 30% Standard Human Insulin Injection), NovoLog (Insulin Aspart [rDNA-derived] Injection), Nplate (Romiplostim), Nutropin (Somatropin for Injection (rDNA-derived)), Nutropin AQ, Nutropin Depot (Somatropin for Injection (rDNA-derived)), Octreotide Acetate Injection (Sandostatin LAR), Ocrelizumab, Ofatumumab Injection (Arzerra), Olanzapine Extended-Release Injectable Suspension (Zyprexa Relprevv), Omnitarg, Omnitrope (Somatropin [rDNA-derived] Injection), Ondansetron Hydrochloride Injection (Zofran Injection), OptiMARK (Gadoversetamide Injection), Optiray Injection (Ioversol Injection), Orencia, Osmitrol Injection in Aviva Container (Mannitol Injection in Aviva Plastic Container 250), Osmitrol Injection in Viaflex (Mannitol Injection in Viaflex Plastic Container 250), Osteoprotegrin, Ovidrel (Chorigonadotropin alpha Injection), Oxacillin (Oxacillin for Injection), Oxaliplatin Injection (Eloxatin), Oxytocin Injection (Pitocin), Paliperidone Palmitate Sustained-Release Injectable Suspension (Invega Sustenna), Pamidronate Disodium Injection, Panitumumab Injection for Intravenous Use (Vectibix), Papaverine Hydrochloride Injection, Parathyroid Hormone, Paricalcitol Injection, in Flip-top Vials (Zemplar Injection), PARP Inhibitors, Pediarix, PEGlntron, Peginterferon, Pegfilgrastim, Penicillin G Benzathine and Penicillin G Procaine, Calcium Pentetate Trisodium Injection (Ca-DTPA), Zinc Pentetate Trisodium Injection (Zn-DTPA), Pepcid Injection (Famotidine Injection), Pergonal, Pertuzumab, PhentolamineMesylate (Pentolamine Mesylate for Injection), Salicylate (Physostigmine Salicylate (Injection)), Piperacillin-Tazobactam Injection (Zosyn), Pitocin (Oxytocin Injection), Plasma-Lyte 148 (Combined Electrolyte Injection), Plasma-Lyte 56 and Dextrose (Combined Electrolyte and Dextrose Injection in 250 Viaflex Plastic Containers), PlasmaLyte, Plerixafor Injection (Mozobil), Polidocanol Injection (Asclera), Potassium Chloride, Pralatrexate Solution for Intravenous Injection (Folotyn), Pramlintide Acetate Injection (Symlin), Premarin Injection (Conjugated Estrogens for Injection), Technetium Tc99 Sestamibi Prep Kit for Injection (Cardiolite), Prevacid IV (Lansoprazole for Injection), Primaxin IV (Imipenem and Cilastatin for Injection), Prochymal, Procrit, Progesterone, ProHance (Gadoteridol Injection), Prolia (Denosumab Injection), Promethazine HCl Injection, Propranolol Hydrochloride Injection, Quinidine Gluconate Injection, Quinidine Injection, R-Gene 10 (Arginine Hydrochloride Injection), Ranibi Zumab Injection (Lucentis), Ranitidine Hydrochloride Injection (Zantac Injection), Raptiva, Reclast (Zoledronic Acid Injection), Recombivarix HB, Regadenoson Injection (Lexiscan), Reglan Injection (Metoclopramide Injection), Remicade, Renagel, Renvela (Sevelamer Carbonate), Repronex (Menotropins for Injection), Retrovir IV (Zidovudine Injection), rhApo2L / TRAIL, Ringer's Solution and 5% Dextrose Injection (Ringers in Dextrose), Ringer's Injection (Ringer's Injection), Rituxan, Rituximab, Rocephin (Ceftriaxone), Rocuronium Bromide Injection (Zemuron), Roferon-A (Interferon alpha-2a), Romazicon (Flumazenil), Romidepsin for Injection (Istodax), Saizen (Somatropin Injection), Sandostatin LAR (Octreotide Acetate Injection), Sclerostin Ab, Sensipar (cinacalcet), Sensorcaine (Bupivacaine Hydrochloride Injection), Septocaine (Articane HCl and Epinephrine Injection), Serostim LQ (Somatropin (rDNA-derived) Injection), Simponi Injection (Golimumab Injection), Sodium Acetate (Sodium Acetate Injection), Sodium Bicarbonate (5% Injection), Sodium Lactate (Sodium Lactate Injection, with AVIVA), Sodium Phenylacetate and Sodium Benzoate Injection (Ammonul), Somatropin for Injection (rDNA-derived) (Nutropin), Sporanox Injection (Itraconazole Injection), Stelara Injection (Ustekinumab), Stemgen, Sufenta (Sufentanil Citrate Injection), Sufentanil Citrate Injection (Sufenta), Sumavel, Sumatriptan Injection (Alsuma), Symlin, Symlin Pen, Systemic Hedgehog Antagonists, Synvisc-One (Hylan GF 20Single intra-articular injection), Tarceva, Taxotere (docetaxel injection), Technetium Tc99m, telavancin injection (Vibativ), temsirolimus injection (Torisel), Tenormin IV Injection (Atenolol Injection), Teriparatide (rDNA-derived) Injection (Forteo), Testosterone Cypionate, Testosterone Enanthate, Testosterone Propionate, Tev-Tropin (Somatropin, rDNA-derived, for Injection), tgAAC94, Thallium Chloride, Theophylline, Thiotepa (Thymoglobulin (Rabbit)), Thyrogen (Thyrotropin Alfa for Injection), Ticarcillin Disodium and Potassium Clavulanate Galaxy (Timentin Injection), Tigan Injection (Trimethobenzamide Hydrochloride Injectable), Timentin Injection (Ticarcillin Disodium and Potassium Clavulanate Galaxy), TNKase, Tobramycin Injection, Tocilizumab Injection (Actemra), Torisel (Temcillin Limus Injection), Totect (Dexrazoxane for Injection, Intravenous Injection Only), Trastuzumab-DM1, Travasol (Amino Acids (Injection)), Treanda (Bendamustine Hydrochloride Injection), Trelstar (Triptorelin Pamoate for Injectable Suspension), Triamcinolone Acetonide, Triamcinolone Acetate, Triamcinolone Hexacetonide Injectable Suspension (Aristospan Injection 20 mg), Triesence (Triamcinolone Acetonide Injectable Suspension), Trimethobenzamide Hydrochloride Injectable (Tigan Injection), Trimetrexate Glucuronide Injection (Neutrexin), Triptorelin Pamoate for Injectable Suspension (Trelstar), Twinject, Trivaris (Triamcinolone Acetonide Injectable Suspension), Trisenox (Arsenic Trioxide Injection), Twinrix, Typhoid Vi, Ultravist (iopromide injection), injectable urofollitropin (Metrodin), urokinase injection (Kinlytic), ustekinumab (Stelara injection), Ultralente(U), Valium (diazepam), Sodium Valproate Injection (Depacon), Valtropin (Somatropin Injection), Vancomycin Hydrochloride (Vancomycin Hydrochloride Injection), Vancomycin Hydrochloride Injection, Vaprisol (Conivaptan Hydrochloride Injection), VAQTA, Vasovist (Gadofosveset Trisodium Injection for Intravenous Use), Vectibix (Panitumumab Injection for Intravenous Use), Venofer (Sugar-Containing Iron Oxide Injection), Verteporfin Injection (Visudyne), Vibativ (Telavancin for Injection), Victoza (Liraglutide [rDNA] Injection), Vimpat (Lacosamide Tablets and Injection), Vinblastine Sulfate (Vinblastine Sulfate Injection), Vincasar PFS (Vincristine Sulfate Injection), Victoza, Vincristine Sulfate (Vincristine Sulfate Injection), Visudyne (Verteporfin Injection), Vitamin B-12, Vivitrol (Naltrexone XR Injection), Voluven (Sodium Chloride of Hydroxyethyl Starch Injection), Xeloda, Xenical (orlistat), Xeomin (Incobotulinumtoxin A for injection), Xolair, Zantac Injection (Ranitidine Hydrochloride Injection), Zemplar Injection (Paricalcitol Injection, in flip-top vials), Zemuron (Rocuronium Bromide Injection), Zenapax (Daclizumab), Zevalin, Zidovudine Injection (Retrovir IV), Zithromax Injection (azithromycin), Zn-DTPA (zinc pentetate trisodium injection), Zofran Injection (ondansetron hydrochloride injection), Zingo, zoledronic acid for injection (Zometa), zoledronic acid injection (Reclast), Zometa (zoledronic acid for injection), Zosyn (piperacillin-tazobactam injection), Zyprexa Relprevv (olanzapine extended-release injectable suspension), and combinations thereof. EXAMPLES
[0100] Example 1: Insert pipe surface finish
[0101] Strips (3 mm x 75 mm) of 22 μm cellulose acetate replication tape (Ted Pella, Inc., Redding CA) were applied to the interior surface of several exemplary insertion tubes. The insertion tubes were formed of stainless steel and prepared generally according to the teachings of U.S. Patent No. 10,369,292 to LaRose. The interior of insertion tubes 1 and 2 were surface treated or finished to reduce or minimize any irregularities located within the tube. The insertion tubes were wetted with acetone and allowed to dry. The cellulose acetate strips were then removed from the insertion tubes using forceps. The strips were mounted on a slide. Replication tape surfaces were measured on a Keyence VK-X100 3D laser scanning microscope (Keyence Corporation, Osaka, Japan) using a 50× objective lens (200 μm x 270 μm field of view), a 2.5 μm S-filter, a 0.1 mm L-filter cutoff wavelength, and curved surface tilt correction. The average surface roughness (S a ) and mean kurtosis (S ku ) was calculated according to ISO 25178-2:2012. The data are shown in Table 1.
[0102] Table 1 shows that insertion tubes 1 and 2 exhibited desirable surface parameters that resulted in successful fastener insertion as indicated by the helium leak rate and the number of lines observed on the front sealing rib of the fastener. In contrast, insertion tubes 3, 4, and 5 did not exhibit desirable surface parameters and did not result in successful fastener insertion. [Table 1]
[0103] The present invention has been described above generally and with respect to specific embodiments. It will be apparent to those skilled in the art that various modifications and variations can be made without departing from the scope of the present disclosure. It is therefore intended that these embodiments cover the modifications and variations of the present invention provided they come within the scope of the appended claims and their equivalents.
Claims
1. 1. A method for inserting a lubricant-free fastener into a lubricant-free barrel, comprising: (A) inserting a stop including at least one sealing rib into a placement area located at a proximal end of an insertion tube, the insertion tube having a body connected to the placement area via a transition zone; (B) lowering the body of the insertion tube into a syringe barrel having a barrel flange past the barrel flange; (C) using an insertion pin to move the stop into the distal opening of the insertion tube; (D) retracting the insertion tube while the stop is retained in a fixed position within the syringe barrel by the insertion pin and the stop is securely positioned within the syringe barrel; and (E) completely retracting the insertion pin and the insertion tube from the barrel to form a stoppered syringe; at least the stopper, the insertion tube, the body of the insertion tube, the syringe barrel, the barrel flange, and the insertion pin are free or substantially free of lubricant; method.
2. The insertion tube has an average surface roughness (S a 2. The method of claim 1 , comprising:
3. The body of the insertion tube has an average kurtosis (S ku 3. The method according to claim 1 or 2, comprising the steps of:
4. The method of any one of claims 1 to 3, wherein the stop is inserted into the insertion tube with a peak insertion force in the range of about 10N to about 200N.
5. The method according to any one of claims 1 to 4, wherein the stop includes at least one sealing rib, the sealing rib having a line count of less than 30.
6. The syringe with stopper is 6 x 10 -6 The method of any one of claims 1 to 5, having a helium leak rate of no more than sccs.
7. The method according to any one of claims 1 to 6, wherein said steps (A) and (B) occur sequentially or simultaneously.
8. The method according to any one of claims 1 to 7, wherein in step (B), a gap is disposed between the insertion tube and an inner surface of the barrel to allow pressure relief.
9. The method according to any one of claims 1 to 8, wherein in step (D), the insertion tube is retracted beyond the insertion pin.
10. The method according to any one of claims 1 to 9, wherein in step (E), the insertion tube and the insertion pin are retracted from the barrel sequentially or simultaneously.
11. The method of any one of claims 1 to 10, wherein the stop comprises an elastomeric body and a polymeric layer thereon.
12. The method of claim 11 , wherein the polymer layer comprises an expanded fluoropolymer.
13. The method of claim 12 , wherein the expanded fluoropolymer comprises expanded polytetrafluoroethylene.
14. 11. The method of any one of claims 1 to 10, further comprising delivering a therapeutic compound to the syringe barrel prior to lowering the insertion tube into the syringe barrel.
15. 15. The method of claim 14, wherein the therapeutic substance comprises a biological compound, a therapeutic compound, or a combination thereof.
16. 15. The method of claim 14, wherein the amount of particles in the barrel is less than about 600 particles / mL for particles greater than 10 μm in size as measured in water for injection (WFI).
17. 15. The method of claim 14, wherein the amount of particles in the barrel is less than 60 particles / mL for particles greater than 25 μm in size when measured in water for injection (WFI).
18. The method of any one of claims 1 to 10 and 15, wherein the insertion tube is electropolished, extrusion horned, or a combination thereof.
19. (A) an insertion tube having a placement area having a diameter for receiving a fastener from a fastener feeder, a body having a diameter smaller than the diameter of the placement area, and a transition zone having a taper angle for transitioning the fastener from the placement area to an insertion tube body; (B) an insertion pin for manipulating the stopper through the insertion tube; and (C) a barrel or cartridge tube having an inner surface for receiving the stop from the insertion tube and the therapeutic substance from the therapeutic feeder; (A)-(C) comprise a system for forming a pre-filled syringe or a pre-filled cartridge, said system and said pre-filled syringe being lubricant-free or substantially lubricant-free; system.
20. 20. The system of claim 19, wherein the taper angle is between about 1 degree and about 20 degrees.
21. The insertion tube has an average surface roughness (S a 21. The system according to claim 19 or 20, further comprising:
22. The insertion tube body has an average kurtosis (S ku The system according to any one of claims 19 to 21, further comprising:
23. The system of any one of claims 19 to 22, wherein the insertion tube is electropolished, extrusion horned, or a combination thereof.
24. The system of any one of claims 19 to 23, wherein the therapeutic substance comprises a biological compound, a therapeutic compound, or a combination thereof.
25. The system of any one of claims 19 to 24, wherein the stop comprises an elastomeric body and a polymeric layer at least partially covering the elastomeric body.
26. 26. The system of claim 25, wherein the polymer layer comprises an expanded fluoropolymer.
27. 27. The system of claim 26, wherein the expanded fluoropolymer comprises expanded polytetrafluoroethylene.
28. 1. A method for inserting a lubricant-free fastener into a lubricant-free cartridge tube, comprising: (A) inserting a stop including at least one sealing rib into a placement area located at a proximal end of an insertion tube, the insertion tube having a body connected to the placement area via a transition zone; (B) lowering the body of the insertion tube into the cartridge tube having an end located just beyond the top of the cartridge tube; (C) moving the stop into the distal opening of the insertion tube using an insertion pin; (D) retracting the insertion tube while the stop is retained in a fixed position within the cartridge tube by the insertion pin and the stop is securely positioned within the cartridge tube; and (E) completely retracting the insertion pin and the insertion tube from the cartridge tube to form a cartridge with a stop; at least the stop, the insertion tube, the body of the insertion tube, the cartridge tube, the top of the cartridge tube, and the insertion pin are free or substantially free of lubricant; method.
29. 30. The method of claim 28, wherein the stop is inserted into the insertion tube with a peak insertion force in the range of about 10N to about 200N.
30. 30. The method of claim 28 or 29, wherein the stop includes at least one sealing rib, the sealing rib having a line count of less than 30.
31. The method according to any one of claims 27 to 30, wherein steps (A) and (B) occur sequentially or simultaneously.
32. The method of any one of claims 28 to 31, wherein in step (B) a gap is disposed between the insertion tube and an inner surface of the cartridge tube to allow for pressure relief.
33. The method according to any one of claims 28 to 32, wherein in step (D), the insertion tube is retracted beyond the insertion pin.
34. The method according to any one of claims 28 to 33, wherein in step (E), the insertion tube and the insertion pin are retracted sequentially or simultaneously.
35. The method of any one of claims 28 to 34, wherein the stop comprises an elastomeric body and a polymeric layer thereon.
36. The method of claim 35 , wherein the polymer layer comprises an expanded fluoropolymer.
37. 37. The method of claim 36, wherein the expanded fluoropolymer comprises expanded polytetrafluoroethylene.
38. 38. The method of any one of claims 28-37, further comprising delivering a therapeutic compound to the cartridge tube prior to lowering the insertion tube into the cartridge tube.
39. 40. The method of claim 38, wherein the therapeutic agent comprises a biological agent, a therapeutic compound, or a combination thereof.
40. The method of any one of claims 28 to 39, wherein the insertion tube is electropolished, extrusion horned, or a combination thereof.
41. The insertion tube has an average surface roughness (S a 41. The method of any one of claims 28 to 40, comprising the steps of:
42. The body of the insertion tube has an average kurtosis (S ku 42. The method of any one of claims 28 to 41, comprising the steps of:
43. The cartridge is 6 x 10 -6 43. The method of any one of claims 28 to 42 having a helium leak rate of no more than sccs.
Citation Information
Cited By
Toothed belt and method for manufacturing toothed belt
CN121701608A
